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ABSTRACT
Purpose: To determine the association of certain aerobic fitness and physical activity genotypes
and the gene-physical activity interaction effect on aerobic fitness in pre-pubertal, African
American, obese children. Methods: Subjects were 30 pre-pubertal, African American, obese
children (9.5 ± 1.7 years) who were free of clinical disease. Height and weight were measured
according to standard procedures. Body fat was assessed using dual energy x-ray absorptiometry,
and DNA samples were collected using buccal swabs. Aerobic fitness was assessed using a
cycle ergometer and the McMaster cycle protocol. ANOVAs were used to determine
associations and interaction effects of the ACE, ADRB2, NOS3, IL6, IGF-1, and APO-E genes,
physical activity and aerobic fitness. Results: Age, height, weight, body mass index, and waist
circumference were significantly lower in girls compared to boys. Subjects averaged
approximately 51 minutes of moderate-to-vigorous intensity activity per day, and girls were
significantly more active than boys. There were no significant associations between the
candidate genes and aerobic fitness level. P > 0.05). There were trends towards significance for
the IL6 rs2069845 gene for absolute and relative VO2peak measures (P = 0.078, and P = 0.094,
respectively). There was also a trend toward significance for the ADRβ2 rs1042717 gene for
leanVO2peak (P = 0.092). Conclusions: In children, further research is needed that includes
diverse populations and large sample sizes in order to more accurately assess the association and
interaction effects of the candidate genes, physical activity and fitness.
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CHAPTER 1:
INTRODUCTION
Low aerobic fitness has been identified as an independent risk factor for cardiovascular
disease in both adults and children.1-2 Specifically, associations between low aerobic fitness,
referred to as fitness for the remaining sections, elevated blood pressure and lipid values, and
obesity have all been shown in the pediatric population, and may play a significant role in the
development of chronic disease later in adulthood.3 In addition, aerobic fitness levels may affect
how physically active a child is by influencing his/her activity intensity. Poor fitness levels may
then translate into lower accumulations of moderate-to-vigorous physical activity during the day
because they are physiologically not able to achieve this intensity. Aerobic fitness is an
important aspect of health, and various factors play an important role in the development and
maintenance of fitness levels including weight status, physical activity levels and genetics.
The prevalence of overweight and obesity is 35.5% of children, ages 6 to 11 years, in the
United States.4 Furthermore, in the African American population, 37.6% of 6 to 11 year old
children are at or above the 85th percentile.4 Not only is high weight status related to increased
number of cardiovascular disease risk factors, but the presence of obesity has also been found to
be inversely related to fitness levels.5 Prior research has shown that weight status and other
factors such as physical inactivity may also negatively impact fitness levels. Therefore, it is
important to better understand variables contributing to fitness within the pediatric population.6
High levels of physical activity have been previously associated with reducing the risk of
all-cause mortality, diabetes, cardiovascular disease in the adult population, and it is possible that
a similar relationship exists within children.7-8 Physical activity has been found to have an impact
on cardiovascular, muscular, and metabolic systems in adults. However, children’s systems are
immature and underdeveloped compared to adults, and therefore may not respond to physical
1

activity in the same ways that adults respond. Previous research has shown that physical activity
has a positive influence on fitness levels in children, however, these studies have only shown a
moderate/weak correlation.9-10
Genetic individuality is another contributing factor to fitness levels. Genetic studies
conducted over the previous years in adults have found that an individual’s genotype may
contribute anywhere from 25 to 66% of the variation in fitness levels,11-16 and because of this
contribution, it is important to assess the associations of certain genes in order to better
understand the individuality contributing to fitness. Unfortunately, none of these studies have
assessed the interaction between habitual physical activity and genotype and the role these two
variables may play on fitness.
Within the integration of genetic and exercise physiology research, the primary physical
trait, or the phenotype, being assessed has typically been a performance-related variable such as
race time. In the case of this study, the phenotype being assessed is aerobic fitness level.
Aerobic fitness is a multi-factorial trait, meaning that an individual’s physical traits being
expressed are influenced by a combination of inherited factors such as the genotype, as well as
lifestyle and environmental interactions.17 As previously mentioned, variations in genotype have
been shown to make up a significant percentage of the variance in fitness levels among adults,
however these relationships have been studied in very little detail in children. Candidate genes
have been identified relating to both fitness and physical activity. The Angiotensin Converting
Enzyme (ACE) gene is related to physical activity and fitness in adults, and β2 Adrenergic
Receptor (ADRβ2), Endothelial Nitric Oxide Synthase 3 (NOS3), Interleukin 6 (IL6), Insulinlike Growth Factor 1 (IGF-1), and Apolipoprotein-E (APOE) are all related to fitness in adults18
and it is possible that these same relationships exist in children.
2

Therefore, there are two main objectives of this study. First, the association of aerobic
fitness genes and fitness will be assessed in a specified population. A better understanding of the
associations will aid in identifying those predisposed to having lower fitness levels. However, in
an attempt to control for the effect of race, maturation status and body composition on fitness
levels and genetic variation, only African American, pre-pubertal, obese children will be
included in the study as the specified population of interest.
The second objective of this study will assess the relationship of physical activity on the
expression of genes and the fitness phenotype, defined as peak oxygen uptake. Since fitness is a
multi-factorial trait that typically involves both an environmental and genetic components, it is
important to assess the interaction that occurs between the two factors in order to better
understand fitness levels of an individual. This concept of a multi-factorial phenotype is the basis
for the assessment of a gene-environment interaction, specifically using physical activity level as
the environment in which the child is exposed. The research questions that will be investigated
in this study are as follows:
Research Question 1:
Is there an association between the aerobic fitness candidate genes and fitness levels in
children?
Hypothesis 1:
Specific genotypes will be significantly associated with the level of fitness.
Research Question 2:
Is there a gene-environment interaction that exists between physical activity levels and
the candidate genes on fitness in children?
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Hypothesis 2:
There will be a significant interaction between physical activity levels and the specific
genotypes on fitness levels in children.
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CHAPTER 2
REVIEW OF LITERATURE
Introduction
A variety of factors contribute to the development of fitness including sex, race, maturity
status, body composition, physical activity and genetics. The interaction between physical
activity, genetics, and fitness has been assessed in the adult population; however research is
limited in the pediatric population. It is essential to assess the relationship between genetics and
fitness in order to understand the impact that interventions and physical activity will play on the
fitness phenotype, with a phenotype being defined as the physical manifestation of the genotype
in an individual. Unfortunately, the influence of physical activity on fitness is equivocal in
previous pediatric literature, and even less is known as to how genetic profile influences the
fitness of children. This study reduces the variation of multiple factors by controlling using a
homogeneous group of pre-pubertal, African American, obese subjects.
The focus of this literature review will be on the contributions of the various factors to
the development of fitness. Additionally, this review will identify candidate genes associated
with fitness and the potential environmental interaction of physical activity and these genotypes.
Aerobic Fitness
Maximal aerobic fitness can be defined as the highest rate at which the skeletal muscles
can utilize the oxygen being delivered during exercise, and is the gold standard for the
measurement of fitness in adults and youth.19 In children and adolescents, the term “peak”
oxygen uptake is becoming more widely used.20 The criteria for VO2max in children includes:
VO2 plateau ( < 2.0 ml·kg-1·min-1 change), RER (>1.05), maximal heart rate (> 190beats min-1),
and a subjective measure of volitional exhaustion. Since children do no often meet these criteria,
5

the peak value attained during the test might be a more reasonable term. Using peak oxygen
uptake as a measure of fitness has been validated in youth.21 The current study will focus on peak
oxygen uptake values. The literature is inconsistent with the use of the terms “maximal” or
“peak” values to define fitness in children. The following section will discuss studies that have
used both maximal and peak values, however findings are generally consistent that higher fitness
levels are associated with positive health outcomes in children.
Poor fitness levels have been associated with increased risk of cardiovascular disease,22-23
metabolic complications, hyperlipidemia, and elevated blood pressure24 in children. 25 An early
study by Fripp et al.22 assessed 37 adolescent boys and found that when divided into three fitness
groups (low, moderate, and high), the high fitness level subjects had fewer cardiovascular
disease risk factors compared to those in the low and moderate fitness level groups. This trend
has been shown repeatedly in the literature, and demonstrates the importance of fitness to
improve health profiles. Ultimately, the research has led to the promotion of fitness for
increased cardiovascular health. However, when comparing fitness levels, it is important to
consider the fact that children experience a change and development in fitness as they age
chronologically and approach maturity. Children’s physiological systems are immature
compared to that of an adult and because adaptations in aerobic fitness differ in children, factors
including weight and pubertal status should be considered when assessing peak fitness.
Aerobic Fitness and Body Composition
As stated earlier, approximately 35.5% of school-aged children in the United States are
categorized as overweight or obese based on body mass index (BMI).4 Due to increasing trends
in high weight status, it is important that the effect of body composition on fitness be considered.
Having a high percentage of body fat has been shown to have detrimental effects on submaximal
6

and maximal fitness in youth. Therefore, high weight status does need to be accounted for when
assessing fitness.
A study by Goran et al.26 assessed 129 pre-pubertal lean and obese children (ages 8.6 ±
1.6 years and 8.9 ± 1.2 years, respectively). Aerobic fitness was assessed using a VO2max
treadmill test to volitional exhaustion, and body composition was assessed using dual energy xray absorptiometry (DXA). It was found that compared to lean children, overweight and obese
children do have a higher absolute VO2max (1.24 ± 0.27 L· min-1vs 1.56 ± 0.40 L· min-1), mainly
because of their larger body size.26 When normalized to relative total body weight, the lean
children had higher VO2max values compared to overweight/obese children (44.2 ± 3.2 ml·kg-1·
min-1 vs. 32.0 ± 4.1 ml·kg-1· min-1). This study demonstrates the inverse relationship between
excess weight and fitness in children. Specifically, overweight and obese children demonstrate a
lower submaximal exercise capacity, as demonstrated by their higher submaximal heart rates,
compared to normal weight children. In addition, the subjects had higher respiratory exchange
ratios, and were working at a higher percent of VO2max during the submaximal stages of the
test.26
Bovet et al.27 assessed 4,599 secondary school children, ages 12-14 years, and found a
significant, inverse relationship between body mass index and fitness level as measured by the
multistage shuttle run. A high fitness level was found in 29.6% of normal weight children
compared to 7.9% of overweight children and 1.2% of the obese children.27 Although fitness
variables were not measured using indirect calorimetry like the previous study, this study
warrants mentioning because it does display dramatic differences in fitness level between
children of different weight status. These results reiterate the importance of accounting for
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weight status, and the negative impact that poor body composition has elicit on fitness levels in
children.
Aerobic Fitness and Racial Differences
It is possible that there are racial differences in aerobic fitness. It has been suggested that
race contributes significantly to the variation in fitness levels.
A study by Trowbridge et al.28 assessed African American and Caucasian children in
order to determine whether or not differences in VO2max existed across racial groups. Results
showed that the African American children had lower VO2max values than Caucasian children
(1.21 ± 0.03 vs. 1.430 ± 0.03 L·min-1, P < 0.01) and remained significant even after controlling
for body weight, lean body mass, total energy expenditure, and activity energy expenditure.
An additional study by Shaibi et al.29 assessed African American, Latino, and Caucasian
children and found that African American children had significantly lower absolute VO2peak
values compared to Latino and Caucasian children (1.57 ± 0.05 vs. 1.68 ± 0.05 vs. 1.84 ± 0.04
L·min,-1 P < 0.05) while controlling for pubertal status, gender and body mass.
These studies clearly demonstrate the association between race and aerobic fitness, and
suggest that racial differences may be in important factor to consider when assessing fitness
levels. These variations could be explained by physiological differences in African Americans
compared to Caucasian and Latino children. For example, African Americans may have lower
hemoglobin levels,30 which may influence the oxygen carrying capacity to the working muscles
during exercise. In addition, differences in skeletal muscle fibers have also been suggested.
Research had suggested that African Americans have a greater percentage of type II fibers.28, 31
Racial differences may also influence physical activity levels28, which may in turn affect the
fitness level of a child.
8

Aerobic Fitness and Sex and Maturity Differences
The sex differences in VO2peak among boys and girls are still somewhat unclear despite
the number of studies that have addressed the issue. Traditionally, pre-pubertal boys exhibit
higher peak VO2 values than girls, and it is estimated that this difference may be 4 to 18% higher
in some cases.32 However, once puberty begins, boys’ relative VO2max tends to maintain, while
girls VO2max declines.33 This trend is evidence that maturation may play an influential role in
aerobic fitness; however, there is little research supporting the relationship. To date, only a small
influence of maturation has been shown to contribute to aerobic fitness (5% in boys and 8% in
girls). More research is needed to better establish the influence of the maturation process on
aerobic fitness. In order to control for the potential effect of maturation on aerobic fitness and
physical activity, only pre-pubertal children were recruited and assessed for this study.
Aerobic Fitness and Scaling of VO2peak
One aspect of aerobic fitness that needs to be considered when assessing fitness in
children is allometric scaling. Instead of reporting O2 uptake in absolute or relative measures, it
may be more appropriate to scale per kilograms of lean body mass. Previous research has
questioned the detrimental effect of excess body fat on aerobic fitness.26, 34 Therefore, it might be
more reasonable to assess oxygen uptake in terms of the lean mass that physiologically
contributes to exercise performance. This lean mass scaling technique has been explored, and
results are equivocal. It is especially important to use scaling when working with obese subjects,
since the contributing factors of aerobic fitness such as lean body mass may be masked by the
high percent fat. Therefore, a better physiological picture might be seen when oxygen uptake is
expressed relative to lean body mass.33
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Davies et al.35 measured body composition and fitness of 17 obese and 17 normal weight
girls and young women in order to assess differences in VO2max using different scaling methods.
There were no significant differences in VO2max (L·min-1) in obese subjects compared to normal
weight subjects. However, when subjects were normalized for lean body mass, the VO2max
decreased by approximately 16% in obese subjects compared to normal weight subjects (44.4 ±
6.5 ml·kgFFM-1·min-1 vs. 53.0 ± 6.9 ml·kgFFM-1·min-1).35 This is an important finding because it
demonstrates the use of normalizing for lean body mass for teasing out differences between
groups. For children, this may be a more beneficial mode of making comparisons.
Normalization is important because it takes into account body composition and calculates
the peak oxygen uptake during a maximal exercise test relative to the lean mass of the subject.
Due to a lack of normalization and varying methods of reporting relative VO2peak values, it is
unclear to what extent body composition influences aerobic fitness within children.
Physical Activity
By definition, physical activity is “any bodily movement produced by skeletal muscle
that results in caloric expenditure.”36 Exercise is defined as “planned, structured, and repetitive
bodily movement done to improve or maintain one or more components of physical fitness.”36 It
is important to note that the primary mode of physical activity in adults is exercise, but physical
activity is much more sporadic and intermittent in children.37 Therefore the benefits that planned
exercise elicits in adults may not apply to children. However, as often seen in adult literature, it
is likely that physical activity positively influences health-related fitness, and therefore
influences cardiovascular health. In addition, it is possible that physical activity may act as a
preventative measure against obesity, as well as function in the treatment for individuals with
increased weight status.38 Based on established evidence supporting this notion, guidelines for
10

physical activity have been established by Strong et al.39 and the US Department of Health and
Human Services.40 These organizations recommend that all youth accumulate 60 or more
minutes of moderate to vigorous physical activity daily.39, 40
Physical Activity Measurements Using Accelerometry
The assessment of habitual physical activity in children can be difficult. However,
advances in devices and methods allow for more accurate physical activity assessment. Activity
monitors, specifically accelerometers, are one way to objectively assess physical activity. These
devices are typically small, computer interfaced monitors that detect bodily movements to
quantify a time and intensity of activity.41 In addition, accelerometers require little burden on the
subject in that they record and store the data, making them ideal for use in youth. It has been
established that in order to capture an accurate representation of habitual physical activity in
children, at least three days with three consecutive hours of wear time must be fulfilled.42 Ideally,
children will wear the monitor for a full seven days with hopes that at least three days, or more,
are valid and usable.42
Evenson et al.43 has validated cutpoints that are used to calculate physical activity based
the number of activity counts accumulated during a 15 second epoch. The study included 33
children who wore the Actigraph and the Actical, as well as a portable metabolic system in order
to determine the validity and reliability of the intensities measured by the accelerometers in 5 to
8 year old children. ROC curves were used to create cutpoints. The cutpoints used for analysis
are as follows: sedentary (0-25 counts), light (26-573 counts), moderate (574-1002 counts),
vigorous (> 1003 counts). The establishment of these cutpoints allows for an accurate
calculation of time spent in various intensities of activity based in the 5 – 8 year old population.
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One of the limitations of accelerometry that needs to be considered is that the devices are
unable to measure static activities such as strength training, and also increases in intensity due to
carrying loads or walking up an incline.38 Even with this limitation, the accelerometer still
allows for an accurate, objective measure of physical activity in children.
Physical Activity and Aerobic Fitness
In adults, there is a direct relationship between physical activity and aerobic fitness.
However, this relationship has not been well established in children. Inactivity is an independent
risk factor of cardiovascular disease, and it has been suggested that physical activity tracks
though childhood, into adolescence and adulthood. Therefore, it is important to determine the
role that physical activity plays in the aerobic fitness level of a child in order to help with
prevention of higher weight status and chronic disease.
A potential complication to the establishment of a clear relationship between physical
activity and fitness in children is the wide variety of methods used to assess children’s physical
activity levels, as well as different modes of assessing and reporting fitness. 44 In a review paper
by Morrow and Freedson,20 the authors discuss numerous studies reporting either no association
or positive associations between activity and fitness. These studies have determined that there
may be a weak correlation between the two variables. Included in the review is a study by
Seliger et al.45 Physical activity was assessed in 12 year old boys using an interview
questionnaire and heart rate monitoring as measures of physical activity, and assessed VO2max
using a cycle ergometer. There were no significant correlations found between fitness and
physical activity. A similar study by Mirwald and colleagues46 assessed physical activity and
VO2max on a treadmill and also did not find any significant associations. LaPorte et al.47 used
questionnaires to assess physical activity and three different tests (mile run, treadmill time to
12

exhaustion, and VO2max) in order to estimate fitness; and similar to the other studies, found no
significant associations.
Despite a number of studies that found no relation between the two variables,
encouraging results linking physical activity and fitness have also been reported. A study by
Rowlands et al.48 found results supporting the positive influence of a child’s physical activity
level on their fitness. Thirty-four subjects, ages 8 to 10 years, were followed for six days using
the Tritrac-R3D activity monitor, and their aerobic fitness was measured using the Bruce
treadmill protocol. Although this study does not include direct measures of oxygen uptake,
authors did use time to exhaustion as an indicator of aerobic fitness. Authors concluded that
there was a positive correlation between the both boys’ and girls’ aerobic fitness and their
activity levels measured in minutes of activity by the Tritrac (r=0.66, P< 0.05).48 This
significant correlation is noteworthy because it demonstrates the importance of physical activity
on overall aerobic fitness. An understanding of how physical activity translates into improved
fitness is equivocal; however these studies may be used to justify the need for physical activity
promotion in both normal weight and high weight status children to improve fitness.
A more recent study by Dencker and collegues44 found similar results to Rowlands in a
group of 248 Swedish children, ages 8 to 11 years old. Aerobic fitness, measured as VO2peak,
was assessed using a cycle ergometer. Results showed that VO2peak was significantly correlated
with activity levels, as measured using an accelerometer, for boys and girls (r = 0.23 and r =
0.23, P < 0.05, respectively).
Overall, research has demonstrated a weak-to-moderate correlation between physical
activity and aerobic fitness within the pediatric population.20 Research with longitudinal,
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objectively monitored physical activity is still needed to assess the dose needed to benefit aerobic
fitness in youth.
Genetic Individuality and Aerobic Fitness
A reasonable argument that may arise when discussing cardiovascular health is the
influence of genetic individuality on our ability to develop, improve and maintain fitness levels.
At the basis of our genetic variation is the allele. Alleles are defined as alternative forms of a
gene, and each different combination of two alleles can then be defined as a genotype. These
different genotypes are responsible for the determination of genetic traits. Observable traits are
then manifested into physical features known as phenotypes. A phenotype is specifically defined
as an observable, physical attribute or property that is genetically controlled, such as hair and eye
color. For this study, the aerobic fitness of an individual is the phenotype of interest.49
Genetic contributions to aerobic fitness were not assessed until the early 1990’s with the
first studies assessing blood cell antigens and enzyme markers and the effects of the markers on
skeletal muscle and endurance phenotypes. In an effort to help establish future research
directions within the fields of exercise physiology and genetics, Medicine and Science in Sports
and Exercise published a series of reports entitled The Human Gene Map for Performance and
Health-Related Fitness Phenotypes18, 50-56 and more recently renamed Advances in Exercise,
Fitness and Performance Genomics.57-58 These review articles provide annual updates of
additions made to the literature. Since its original publication in 2001, hundreds of articles
examined the relationships found between performance and genetics. The published studies
have aided in identifying key candidate genes contributing to health-related fitness which include
hemodynamics such as heart rate, blood pressure, and heart morphology, as well as body
composition, anthropometry, insulin, glucose metabolism, blood lipids, lipoproteins, and
14

hemostatic factors during exercise.50 The following sections will discuss the relationships found
between six of the determined aerobic fitness candidate genes and aerobic fitness.
Angiotensin Converting Enzyme Gene and Aerobic Fitness
To date, the Angiotensin Converting Enzyme (ACE) gene is the most widely studied
candidate gene in the field of exercise physiology. The ACE gene contributes significantly to the
function of the renin-angiotensin system and is primarily responsible for converting Angiotensin
I to Angiotensin II, as well as for its role in facilitating the degradation of vasodilatory
substances in order facilitate an increase in blood pressure.59 Since ACE plays a primary role in
the renin-angiotensin system, down-regulation of ACE may be beneficial, since high levels of
ACE may predispose an individual to high blood pressure. Higher circulating levels of ACE are
most commonly associated with specific genotypes, whereas lower circulating levels have been
found within different genotypes.
The relationship between ACE and aerobic fitness is unclear and requires further
investigation in order to determine if the relationship holds true. The gene’s association to
fitness has shown equivocal results due to the large number of studies done in which both
significant and non-significant results have been determined.
Previous case-control studies have found consistent results demonstrating that the ACE
I/I genotype is more prevalent in athletes than in the controls. The first article known to date
assessing the relationship between ACE and performance was published in 1998 by Gayagay et
al.60 This study included 64 Australian national rowers, and found that compared to a normal
population, the rowers exhibited a higher distribution of the ACE I allele and ACE I/I genotype.
Myerson et al.61 published results demonstrating that within a group of 1,086 elite runners, there
was an increasing frequency of the I allele as the distance of the runner’s event increased, when
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compared with a non-athlete control group (0.35, 0.53, 0.62 for < 200 m, 400-3000 m and >
5000 m, respectively).61 Previous studies have also demonstrated findings similar to these
within marathon runners.62
The HERITAGE study is one of the largest data sets of genetic and health-related
outcomes. A study by Rankinen et al.63 of the HERITAGE group reported insignificant
differences between the ACE genotype and VO2max after a training program. The training
program does show how individuals with differing genotypes may respond to exercise, and
mimics, to an extent, the influence habitual physical activity may play. The study included 724
adults who were healthy and sedentary, and participated in a 20-week endurance training
program.63 Across genotypes, VO2max values were not different, however parents and children
with the DD genotype did show increases in VO2max following the training program. Although
findings were not significant, the results do indicate the potential relationship between ACE and
cardiorespiratory fitness in both adults and children.
These studies demonstrate that there may be a potential association between the I allele of
the ACE gene and improved endurance performance. The ACE gene is an important candidate
gene not only because of the extent to which is has been studied, but also because of the role the
renin-angiotensin system plays in exercise response. It is important that we better understand
individual blood pressure responses and how that affects fitness levels and responses to exercise.
If varying responses are present among genotypes, then individuals may respond differently to
training programs.
β-2 Adrenergic Receptor Gene and Aerobic Fitness
The β-2 adrenergic receptor (ADRβ2) is involved in many different critical pathways related to
aerobic fitness. These receptors are located on the plasma membrane of the cell, and are
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responsible for binding with primarily epinephrine in order to initiate the adenylate cyclase
cascade. This adenylate cyclase cascade then goes on to stimulate cyclic adenosine
monophosphate (AMP) in order to alter the rate at which cellular processes, such as fat
metabolism, occur.64
The primary effect of the β-2 adrenergic receptor is to increase both bronchodialation and
vasodilation,65 and although lung function is not a limiting factor in most aerobic activities,
peripheral vasodilation is an important aspect of aerobic performance and ultimately fitness
levels. Therefore, the ADRβ2 gene is a potential candidate gene because of its function in
cardiovascular responses to exercise such as vasodilation21 as well as its regulation in lipid
mobilization from adipose tissue. 66 Obesity, activity, and the ADRβ2 gene have been previously
assessed in a study by Meirhaeghe et al.,67 which found that sedentary men with the Gln27Glu
polymorphism of the ADRβ2 gene had a nearly 3.5 times greater risk of developing obesity
compared to active men. However, the relationship between activity, aerobic fitness and ADRβ2
has not been assessed in detail. Since fitness is a moderator in the development of obesity, it is
important that we explore this relationship as well.
ADRβ2 has two commonly studied alleles, Gln and Glu, located at the ADRβ2 codon 27,
which can be combined to form three different genotypes: Gln27Glu, Glu27Gln, and Glu27Glu.
A study by Moore et al.68 assessed the Gln27Glu polymorphism, and its association with aerobic
fitness in a group of 63 non-obese, postmenopausal women who were categorized as either
sedentary or athletic. Results of the study showed that women with the ADRβ2 Glu27Glu
genotype had a higher weight, higher BMI, and lower VO2max when compared with the ADRβ2
Glu27Gln and ADRβ2 Gln27Gln. The study concluded that Glu27Gln and Gln27Gln were
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significantly associated with aerobic performance within older women compared with the
Glu27Glu genotype.
A similar study by Macho-Azcarate et al.69 determined that in obese women Glu27Glu
genotype, there were significantly lower rates of fat oxidation compared to obese women with
the Gln27Gln genotype. It has been previously shown that the ADRβ2 gene may be linked with
a higher BMI measurement and higher fat mass.68, 70 These studies demonstrate that there is a
relationship between a ADRβ2 polymorphism, specifically the Glu27Glu genotype, and lower
oxygen consumption.
Another instrumental study on the role of ADRβ2 and aerobic performance is that of
Wolfarth et al.66 This case-control study included 297 sedentary controls and 313 male elite
endurance athletes, and found that a different genotype, the Arg16Gly genotype, was associated
with increased aerobic performance. In addition, when compared to carriers of the Gly allele, it
was found that the Gly allele elicits an unfavorable effect regarding endurance performance and
that increases in oxygen consumption may be partially attributed to the possession of the Arg
allele within the ADRβ2 gene.
Although there have been significant relationships found between the ADRβ2 gene and
aerobic fitness, research is still needed to determine the extent to which the gene plays a role in
lipid metabolism during aerobic activity and how different polymorphism may or may not
determine how aerobically fit an individual may become. Currently, there is no research on the
relation of the ADRβ2 gene and fitness in children, and it is critical that we explore how this
gene influences fitness in children since their lipid metabolism may function differently
compared to adults.
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Endothelial Nitric Oxide Synthase Gene and Aerobic Fitness
The Endothelial Nitric Oxide Synthase Gene (NOS3) is one of three genes primarily
involved in the mediation of nitric oxide. The release of nitric oxide causes the relaxation of
blood vessels in order to facilitate a reduction in blood pressure.71
As previously mentioned, most genetics research in relation to exercise response deals
with the area of sport performance. One of the first studies done assessing NOS3 and aerobic
performance was done by Saunders et al.72 This was a case-control study and included Ironman
triathlon finishers and a group of controls. Specifically, authors were interested in exploring the
role of the kallikreinkinin system (KKS) and the degradation of bradykinin in order to elicit an
increased release of the vasodilator nitric oxide (NO) by determining the association between
triathlon finishing times and certain NOS3 polymorphisms related closely to the KKS and nitric
oxide mechanism. Since the production of NO is controlled within the NOS3 gene, it is
important to assess the gene’s polymorphisms and how these differences might influence
performance in endurance events. The triathlon finishers’ times were divided into tertiles, and it
was found that the prevalence of the NOS3 GG genotype increased as the finishing times
decreased [fastest times (35.0%) vs. middle times (40.4%) vs. slowest times (46.9%)] compared
to the GA or AA genotype.72 Therefore, it may be possible that those athletes with the slowest
times and the GG genotype may have decreased NO production.
Although this study by Saunders et al.72 focuses on performance within a sample of
athletes, the findings help to establish a relationship between the cardiorespiratory system and
the NOS3 genotype. The mechanisms proposed by the authors that the NOS3 gene plays a key
role in endurance type activities can be applied to populations outside athletics as well, since the
role of vasodilation and mitochondrial metabolism are essential to a wide variety of endurance
19

activities, either performance or health-related. This relationship can be used as building block
for research questions aimed at a better understanding of aerobic fitness and how an individual’s
genetic background might dictate some aspects of fitness and the cardiorespiratory system.
Although there have been few studies assessing the relationship of NOS3, the studies
have had a wide variety of variables and populations assessed. Hand and colleagues73 assessed
the NOS3 gene and the G894T and T-786c polymorphism in order to determine whether or not
relationships in exercise hemodynamics, including heart rate, blood pressure, cardiac output,
stroke volume, arteriovenous oxygen difference (a-vO2 diff), and total peripheral resistance
existed among different polymorphisms. Subjects included 63 postmenopausal women who
were divided into three groups: sedentary, physically active and endurance trained. No
significant NOS3 G894T allele differences for habitual physical activity, blood pressure, cardiac
output or a-vO2 differences were noted. There were differences in both submaximal and
maximal heart rate. Specifically, non-carriers of the G894T genotype had higher submaximal
exercise heart rates than the carriers (120 ± 2 vs. 112 ± 2 bpm, P = 0.007). Non-carriers also had
higher maximal heart rates during exercise testing (165 ± 2 vs. 158 ± 2 bpm, P = 0.04).73 G984T
heterozygote genotypes tended to have higher stroke volume compared to the non-carriers during
both submaximal and maximal exercise (78 ± 2 ml/beat vs. 72 ± 2 ml/beat, P = 0.03, and 70 ± 2
ml/beat vs. 64 ± 2 ml/beat, P = 0.08, respectively).73
One of the main strengths of the study by Hand et al.73 was the inclusion of a variety of
different activity levels. By including sedentary, physically active and trained individuals, the
authors were able to get a basic understanding of exercise hemodynamics and how the NOS3
G894T genotype is distributed among the wide range of exercise responses. These findings are
an important contribution to the literature due to the applicable nature of their outcome variables
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in many different populations. A better grasp of how individuals with different genotypes will
respond to graded exercise testing in terms of heart rate and stroke volume responses, both which
are important to an individual’s aerobic fitness, may help with future testing and exercise
prescription.
Interleukin – 6 Gene and Aerobic Fitness
The role of the Interleukin – 6 (IL6) gene lies primarily in the role of inflammation and
the maturation of Beta cells, and is released mainly at the site of both acute and chronic
inflammation. This cytokine is also discharged into the bloodstream following a muscle
contraction, and acts in decreasing insulin resistance and also increasing lipid breakdown within
the individual. Previous studies have linked individuals with high IL6 markers and C-reactive
proteins (CRP) with the development of Type II Diabetes, decreased muscle mass, decreased
muscular strength, as well as risk of low fitness levels.74-75 Low fitness levels may be the result
of negative atherosclerotic changes in the artery elicited by high circulating inflammatory
markers, specifically IL6 and CRP. Inversely, high fitness levels could possibly offset the
damages caused by circulating inflammatory markers. These potential implications related to
high levels of circulating IL6 and CRP, deem it necessary to assess the effect of this gene on
aerobic fitness, and also its interaction with physical activity on fitness.
Fitness and physical activity have both been linked with the IL6 gene,76 showing an
inverse relationship between individuals with a lower fitness typically have inflammatory and
markers such as IL6 as well as CRP. A study by Isasi et al.76 assessed physical fitness and CRP
levels of 205 subjects, ages 6-24 years. In the study, fitness was measured using a treadmill test,
and the study determined that fitness and CRP levels were inversely related, meaning that as an
individual’s fitness decreased, their CRP levels increased.
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Ortlepp et al.77 assessed a group of 1,929 healthy young male smokers, and a secondary
objective of the study was to determine the relationship of the IL6 gene to physical fitness.
Physical fitness was measured using a cycle ergometer, and genotyping was determined using
blood samples. Results of the study demonstrated that those who smoked and had the C/C
genotype had lower aerobic fitness than those individuals who smoked with the G/G genotype.77
However, within non-smokers, there were no differences in aerobic fitness.
Although these studies do not directly assess the IL6 gene’s involvement in aerobic
fitness, the gene’s function in the production of inflammatory markers, including CRP levels,
warrants the assessment of how the gene may relate to aerobic fitness.
Insulin-Like Growth Factor - I Gene and Aerobic Fitness
The Insulin-like Growth Factor – 1 (IGF-1) gene regulates cell growth and differentiation
in a variety of different ways, including the growth of cartilage, bone, muscle and other tissues.
More specifically within the skeletal muscle, IGF-1 has been associated with increased muscle
protein content, reduced muscle degradation, and hypertrophy of skeletal muscles. In addition,
due to its relationship with insulin sensitivity, IGF-I is also heavily involved with glucose uptake
into the muscles.78-81
Possibly the most significant study on IGF-1 and its relation to fitness was done by
Lopez-Alarocon et al.80 The group assessed the IGF-I189 polymorphism(189/189 and 189/NC)
and those who were non-carriers of the polymorphism (NC/NC), and its association with lean
mass, exercise economy, and exercise performance, all of which play a role in aerobic fitness.80
The research involved 114 sedentary women, all of whom were genotyped for the IGF-I189
polymorphism, and then assessed their endurance performance and submaximal oxygen
consumption as markers for fitness. The results demonstrated significantly longer treadmill
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times with the IGF-1189 genotype (189/189 and 189/NC) compared to the NC/NC genotype. In
addition, as a submaximal workload, there was a negative association between oxygen uptake
and the carriers of the polymorphism.80 A negative association indicates lower energy
expenditure at submaximal workloads, and a higher exercise economy. This may translate into
improved fitness in individuals with the heterozygote IGF-1189.
These results support the potential influence of the IGF-1 gene on fitness in adults, and it
is possible that a similar relationship exists in children. Due to the IGF-1 gene’s function in
skeletal muscle and growth, as well as insulin sensitivity, it is also possible that in the selected
population of this study, there may be a wide variation of fitness values associated with the IGF1 polymorphism due to the potential for increased insulin resistance in children of a higher
weight status.
Apolipoprotein-E Gene and Aerobic Fitness
Apolipoprotein-E gene (APO-E) is responsible for making the protein, Apolipoprotein,
which fuses with lipids in order to form the lipoproteins necessary for the carrying of cholesterol
throughout the bloodstream. More specifically, APO-E functions in the production of very low
density lipoproteins, which are used in the transport of excess cholesterol for hepatic breakdown,
and aiding in triglyceride clearance.82 The APO-E gene is considered a candidate gene for this
study due to its relationship to lipid transport and breakdown, as well as for the role that physical
activity plays on the regulation of cholesterol regulation. Most research concerning the APO-E
gene has been done in terms of the body’s response to exercise training. The rationalization for
exercise training programs is because APO-E has been shown to be responsible for lipid
transport, and literature has demonstrated that physical activity may aide in maintaining healthy
lipid profiles.
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A study by Leon et al.83 explored the APO-E gene through a variety of questions, one
being how APO-E influences an individual’s aerobic fitness both at baseline and following a 20week training program. The results demonstrated that there were no differences in maximal
aerobic fitness at baseline or 20 weeks across the different APO-E genotypes. Although there
were no differences shown, it does establish the need for more detailed research on the APO-E
gene because of the strong associations shown between cardiovascular fitness profiles and
physical activity.
A similar study done by Thompson et al.84 assessed a group of 120 males and females
who were equally distributed for the APO-E genotypes E2/3, E3/3, and E3/4 genotypes. Results
showed that there were no differences between the E2/3, E3/3, and E3/4 genotypes at baseline
(2.49 ± 0.86 L·min-1 vs. 2.62 ± 0.75 L·min-1 vs. 2.57 ± 0.76 L·min-1; P = 0.753, respectively).84
However, there was a significant increase in VO2max following the 24 week aerobic exercise
program among the three genotypes (0.30 ± 0.39 L·min-1 vs. 0.09 ± 0.25 L·min-1 vs. 0.34 ± 0.32
L·min-1; P = 0.001, respectively).84 The exercise training program applied by Thompson and
colleagues84 did demonstrate differences after a 24-week exercise training program that included
exercise sessions where individuals exercised at 60 – 85% of their maximal oxygen uptake and
the findings suggest that individuals with various APO-E genotypes may respond differently to
exercise. This relationship between APO-E, exercise and improved aerobic fitness is
encouraging because it suggests that genetic profiling may aid in the implementation of an
exercise prescription that is going to be most effective for the individual.
The obesity epidemic implies that there is an increase in unhealthy lipid profiles of
adults and children. Previous literature has shown a significant relationship between coronary
artery plaque and dyslipidemia in youth,85 and additional information is need to establish how
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improvements in aerobic fitness may help modify these risk factors. Since aerobic fitness may
vary among APO- E genotypes, it is important that we assess this gene in more detail in order to
better understand physiological responses to exercise and physical activity. Although there is
little research on the associations between APO-E genotype and aerobic fitness, it is necessary
that we explore this relationship in children in order to delay the onset of cardiovascular disease
through the use of proper exercise and physical activity prescription.
Gene-Physical Activity Interactions and Aerobic Fitness
As stated earlier, a gene-environment interaction (GxE) study is one way of assessing the
interaction between habitual physical activity, the identified candidate gene, and the outcome
variable. By definition, a GxE may influence the outcome variable in two different ways. The
first mode by which a GxE may influence is to assess the effects of varying environments, such
as physical activity levels, and how that environment may influence individuals with the same
genotype. The second mode is to assess how the same environment, such as a physical activity,
affects individuals with different genotypes.86 Although research in this field is limited, there
have been studies done highlighting the influence of genes and an individual’s environment on
key factors pertaining to fitness. Studies have linked certain genes to cardiovascular disease risk
factors including aerobic fitness (ACE), obesity (ADRβ2), blood lipids (APO-E), and blood
pressure (ACE) in adults. It is unknown whether these genes act in a similar manner in children
compared with adults or if the mechanism of an environmental factor (inactivity or activity) alter
the gene expressions from childhood into adulthood.
Unfortunately, the vast majority of studies assessing the gene-physical activity interaction
do not use aerobic fitness as the outcome variable. Instead, the studies’ outcome variables are
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critical cardiovascular phenotypes that contribute to overall fitness. This section will focus
primarily on those studies and their potential relationship to fitness in children.
A study by Hagberg et al.87 assessed the effect of the ACE II, ID, and DD genotypes on
VO2max among a group of postmenopausal women with varying physical activity levels. The
study determined that there was no significant interaction between the different genotypes and
physical activity levels on VO2max, indicating that the influence of genotype on fitness was
relatively similar across all physical activity levels (II, 33.4 ± 7.6 vs. ID, 30.1 ± 8.5 vs. DD, 27.1
± 5.8 ml·kg-1·min-1). It has been established that the ACE gene is related to fitness; however to
what extent the gene dictates a fitness level is unknown. Gene interaction studies such as this are
crucial to the understanding of how genetics contributes to fitness across a variety of physical
activity levels.
Additional GxE studies on physical activity and fitness focused on fitness level, but also
include hemodynamic responses in order to potentially tease out if certain hemodynamic factors
of fitness have an increased genetic contribution. Roltsch et al.88 not only assessed fitness
(VO2max), but also variables of submaximal and maximal exercise including: cardiac output,
stroke volume, heart rate, blood pressure, total peripheral resistance and arteriovenous oxygen
difference. Results found that, similar to Hagberg et al.87 that there were no significant
associations of the ACE II, ID or DD genotypes on hemodynamic responses or VO2max. In
addition, there was no significant interaction effect of genotype and physical activity level on
VO2max, indicating that genotype effect was consistent across sedentary and endurance-trained
young women.88
A third study assessing the GxE question includes the ADRβ2 gene. McCole et al89
assessed the ADRβ2 and ADRβ3 gene in 62 postmenopausal women in order to help better
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understand the influence of genotype and habitual physical activity on fitness levels. Physical
activity was self-reported, DNA samples were obtained via venous blood samples, and aerobic
fitness was assessed using a VO2 submaximal and maximal treadmill test. Results of the study
showed that there were significant interactions between ADRβ2 genotype and submaximal avO2 differences in the adult women, however there was no significant interaction effect between
the Gln/Gln, Gln/Glu, and Glu/Glu genotypes and physical activity levels on VO2max (Gln/Gln,
29.1± 1.6 vs. Gln/Glu 32.4 ± 1.4 vs. Glu/Glu 24.8 ± 2.5 ml·kg-1·min-1).89 Despite the lack of a
significant interaction of genotype and physical activity, it was still determined that there were
statistically different VO2max differences between genotype groups. This finding is important
because it reiterates the potential genetic differences in fitness, and provides evidence that a GxE
may still exist despite the study’s findings.
Unfortunately, the limited research on the gene-physical activity interaction has shown
inconclusive results in adults. Previous GxE studies have included the ACE and ADRβ2 gene,
but due to the associations found between the remaining candidate genes of this study (NOS3,
IGF-1, IL6 and APO-E) and fitness, all six will be assessed in terms of a GxE.
Summary
Although there have been a number of studies done assessing genetic variation, the
majority of the research on aerobic fitness, physical activity and each of the genes discussed in
the earlier sections conducted in the field of genetics have been done in adults. It is important
to note that it is likely that the mechanisms that occur in adults likely occur in a similar manner
in children, but also that the impact of physical activity on aerobic fitness in children is not as
well established. However, due to the limited increasing health risks related to low physical
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activity and fitness in children, it is critical that we explore these potential relationships within
the pediatric population.
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CHAPTER 3: MANUSCRIPT
Abstract
Purpose: To determine the association of certain aerobic fitness and physical activity genotypes
and the gene-physical activity interaction effect on aerobic fitness in pre-pubertal, African
American, obese children. Methods: Subjects were 30 pre-pubertal, African American, obese
children (9.5 ± 1.7 years) who were free of clinical disease. Height and weight were measured
according to standard procedures. Body fat was assessed using dual energy x-ray absorptiometry,
and DNA samples were collected using buccal swabs. Aerobic fitness was assessed using a
cycle ergometer and the McMaster cycle protocol. ANOVAs were used to determine
associations and interaction effects of the ACE, ADRB2, NOS3, IL6, IGF-1, and APO-E genes,
physical activity and aerobic fitness. Results: Age, height, weight, body mass index, and waist
circumference were significantly lower in girls compared to boys. Subjects averaged
approximately 51 minutes of moderate-to-vigorous intensity activity per day, and girls were
significantly more active than boys. There were no significant associations between the
candidate genes and aerobic fitness level. P > 0.05). There were trends towards significance for
the IL6 rs2069845 gene for absolute and relative VO2peak measures (P = 0.078, and P = 0.094,
respectively). There was also a trend toward significance for the ADRβ2 rs1042717 gene for
leanVO2peak (P = 0.092). Conclusions: In children, further research is needed that includes
diverse populations and large sample sizes in order to more accurately assess the association and
interaction effects of the candidate genes, physical activity and fitness.
Introduction
Low aerobic fitness has been identified as an independent risk factor for cardiovascular
disease and increased mortality in both adults and children.1-2 Specifically, associations between
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aerobic fitness, referred to as fitness for the remainder of the paper, blood pressure, lipid values,
and obesity have all been shown in the pediatric population, and may play a significant role in
the development of chronic disease later in adulthood.3 Aerobic fitness is an important aspect of
health, and various factors play a key role in the development and maintenance of fitness levels
including weight status, physical activity levels, and genetics.
Weight status may play one of the most important roles in relation to fitness.
Approximately 35.5% of children, ages 6-11 years, in the United States fall at or above the 85th
percentile for Body Mass Index (BMI) using Centers for Disease Control and Prevention (CDC)
age- and sex- growth charts.4 Furthermore, in the African American population, 37.6% of 6-11
year old children are above the 85th percentile.4 Not only is high weight status related to an
increased number of cardiovascular disease risk factors, but the presence of obesity has also been
found to be inversely related to fitness levels.5 Research has shown that physical inactivity may
also negatively impact fitness levels. Therefore, it is important to better understand variables
contributing to fitness within the pediatric population. 6
High levels of physical activity are associated with reducing the risk of all-cause
mortality, diabetes, and cardiovascular disease in the adult population, and it is possible that a
similar relationship exists in children.7-8 Previous research has shown that physical activity is
positively associated with aerobic fitness in children; however, these studies have only shown
moderate/weak correlations.9-10 Research has also shown that race and maturation may also
influence the fitness level of a child.29, 90-91
Genetic make-up is another contributing factor to fitness levels. Genetic studies have
only been conducted in adults and have found that an individual’s genotype explains a portion of
the variability (25-66%) in fitness.11-16 Unfortunately, few studies87-89 have assessed the
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interaction between habitual physical activity and genotype and the role these two variables may
play on fitness.
Aerobic fitness is a multi-factorial phenotype, meaning environmental interactions (i.e.
lifestyle, diet) play a role in the development of fitness.17 Candidate genes have been identified
that relate to both aerobic fitness and physical activity. Angiotensin Converting Enzyme (ACE)
is the gene associated with physical activity and fitness in adults, and the remaining genes β2
Adrenergic Receptor (ADRβ2), Endothelial Nitric Oxide Synthase 3 (NOS3), Interleukin 6
(IL6), Insulin-like Growth Factor 1 (IGF-1), and Apolipoprotein-E (APO-E) are all related to
fitness in adults. 18 These candidate genes have been established in the adult literature, and it is
possible that these same relationships exist in children. In order to control for the effect of race,
maturity, and body composition on fitness levels and genetic variation, only African American,
pre-pubertal, obese children will be included in the study.
Therefore, the purpose of this study was to determine the association of genotype and
fitness in the specified population. A secondary purpose of the study was to assess the interaction
effect of genotype and physical activity level on aerobic fitness.
Methods
Study Participants
Subjects were 30 African American children (boys aged 6-12 years old and girls aged 6-9
years old) who were obese, pre-pubertal, and had no clinical diagnosis of any other physical
disease except obese weight status.
Recruitment and Testing Sites
This was a multi-site study that included clinics in Memphis, TN and Knoxville, TN.
The Memphis site was overseen by pediatric endocrinologists at a diabetes and obesity lifestyles
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clinic. The Knoxville site included pediatricians at a weight management clinic. These sites
specialized in the care of overweight and obese children, and assessed pubertal status as standard
of care.

Primary recruitment of the subjects was performed by a study investigator during, or
shortly after, the child’s initial visit to one of the clinics. During the initial visit to the pediatric
endocrinologist or pediatrician, BMI was calculated, pubertal status was assessed, and
inclusion/exclusion criteria were determined by the physician, and once the child was screened
and deemed eligible for the study, the parent and child were contacted.
Assessments were conducted at either the Memphis site [University of Tennessee
Clinical and Translational Institute, General Clinical Research Unit (CTSI/CRU)] or the
Knoxville site [University of Tennessee, Applied Physiology Laboratory (APL)].
Subject Screening
The screening was conducted at the clinics. Height and weight were measured, and used
to calculate a BMI percentile based on CDC age and sex-specific growth charts.92 The percentile
was then used to determine eligibility for the study and all children at or above the 95th percentile
were considered eligible. The race of the child was reported by parents/guardian at the child’s
initial clinic visit.
Pubertal status was determined by stages using of Tanner’s Criteria.93 Medical
practioners assessed developmental stages by examining the breasts (girls), genitals (boys) and
pubic hair (girls and boys). This is part of the standard evaluation at the selected clinics.
Children who were classified as Stage 1 or 2 for all variables were considered pre-pubertal, and
therefore eligible for inclusion in the study.
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Exclusion criteria for the study included diagnosis of disease as well as contraindications
for maximal exercise testing in children. These criteria included: children being treated with
medication for hypertension and/or diabetes, heart disease (including inflammatory cardiac
disease), pulmonary disease, acute renal disease, acute hepatitis, drug overdose affecting the
cardiorespiratory response to exercise, severe aortic or pulmonary stenosis, serious ventricular
dysrhythmia, seizure disorder, hemorrhagic disease or asthma with the use of medication within
the previous two weeks or a hospital/emergency room visit within the past year.94
Initial Visit
Upon arriving at the CTSI/CRU or APL, informed written consent was obtained from
the parent or guardian of the child. Informed, written assent was obtained from the child. All
subjects were asked to fast for at least four hours prior to the appointment and instructed to wear
comfortable, loose fitting clothes and closed toe shoes.
Anthropometrics
Height and weight were assessed using standard procedures95, and anthropometrics were
then used to calculate (BMI). CDC BMI-for-age and sex-specific growth charts were then used
to determine BMI percentile.92 Waist circumference measurements (cm) were also obtained
using a Gulick tape measure at the end of normal expiration halfway between the last rib and the
iliac crest.95
Body Composition
Body composition was assessed by certified X-ray technicians via dual energy X-Ray
absorptiometry (DXA) using a Hologic Discovery-A Fan Beam Bone Densitometer (S/N 80044)
at the CTSI/CRU or GE Medical Systems Lunar IDXA (40782) at the APL. Previously
measured height and weight were used for analysis. Subjects’ hands and feet were secured in
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place in order to avoid unwanted movements during the body scan. The scan took approximately
10 minutes to complete and was analyzed using pediatric software. Lean mass (kg), fat free mass
(kg) and percent fat were used in analysis.
Aerobic Fitness Test
Aerobic fitness was assessed using a cycle ergometer. Prior to testing, resting systolic
and diastolic blood pressure and heart rate were measured using an automatic blood pressure cuff
(OMRON, Vernon Hills, IL), and the testing protocol was described to the subject in detail. The
McMaster Cycle Protocol (Table 1) required the subject to pedal at 50 rpm and the initial
workload was determined based on the child’s height (cm). The test was a continuous protocol
that increased in intensity every two minutes until volitional exhaustion.
Subjects were fitted with a face mask to continuously measure oxygen consumption
(VO2) and carbon dioxide production (VCO2) throughout the test using a metabolic system
[CardioCoachCO2 Model 9000, Korr Medical Technologies (Salt Lake City, UT) or the Oxycon
Mobile portable metabolic system (CareFusion, Yorba Linda, CA)]. Peak oxygen
Table 1: McMaster Protocol
Rate (RPM)

Height (cm)

Initial
Load
Watts (W)

50

<120

12.5

12.5

2

50

120-140

12.5

12.5

2

50

140-160

25

25

2

25

50.0 (males)
25.0
(females)

2

50

>160
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Increment
Watts (W)

Stage
Duration
Minutes (min)

uptake (VO2peak) was determined as the highest value obtained during the last stage of the test.
Calibration of the metabolic equipment was completed prior to each test. Telemetry was used to
continuously monitor heart rate during the test (Polar, Lake Success, NY). During the last 15
seconds of each exercise stage, the subject was asked to point out their rating of perceived
exertion (RPE) on the OMNI Scale96 (Appendix C). The RPE scale ranges from 0 – 10 and
includes pictures in order to better assess how hard the subjects feel they are working during the
stage. Subjects’ HRpeak, RERpeak, RPE, test time were measured, and peak MET level was
calculated from the values obtained during the cycle test. The test was stopped when subjects
could no longer maintain the pedal cadence, or requested to stop. Subjects were then asked to
cool down for at least five minutes at a self-selected pace. The subjects’ VO2peak was determined
as the highest value attained during the last 30 seconds of the final stage.
Physical Activity Assessment

The Actigraph GT3X (Pensacola, FL) was used to assess each subject’s habitual physical
activity. The monitor is tri-axial and was set to 15 second epochs in order to capture the
subject’s activity as accurately as possible. The cutpoints used have been validated in this
population by Evenson et al.43 Cutpoints for each intensity were set at: sedentary (0-25 counts),
light (26-573 counts), moderate (574-1002 counts), vigorous ( > 1003 counts). It is
recommended at least three days of activity are monitored to ensure a correct representation of
the subject’s habitual activity.42 The Actigraph was placed on an elastic belt around the waist and
worn over the right hip for seven days. After monitoring was complete, the subject placed the
Actigraph in a pre-paid, stamped and addressed box and sent it back to the study investigator.
Actilife software was used to download the data. Data was then designated into four difference
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intensity categories (sedentary, light, moderate, and vigorous) using pre-determined activity
count cut points and validated regression equations.43 The number of minutes and percentage of
time spent at each intensity was then calculated.
DNA Sample
Each subject’s DNA was obtained by the primary investigator using buccal brushes. In
order to maximize the yield of DNA from the brush, two samples were obtained. Before
swabbing, each subject was instructed to rinse his/her mouth thoroughly twice with water for 30
seconds each time. DNA collection was done by firmly rolling the brush on the inside of each
cheek for 20 seconds on each side. The brush was then placed in a sterile area where it was set
to dry for at least 15 minutes, and then placed into a -20⁰C freezer for storage until analysis took
place.
DNA Extraction and Genotyping

DNA extraction from the buccal swabs is done based on protocols from Epicentre
Biotechnologies (Madison, WI).97 Genotypes were determined using the Applied Biosystems
Instruments by LifeTech (Carlsbad, CA) Prism 7000, Taqman single nucleotide polymorphism
microarrays, and SDS software.
Single nucleotide polymorphism (SNP) identification markers were identified for the
following genes: Angiotensin Converting Enzyme (ACE), β2 Adrenergic Receptor (ADRB2),
Nitric Oxide Synthase 3 (NOS3), Insulin-like growth factor 1 (IGF1), Interleukin 6 (IL6), and
Apolipoprotein E (APO-E). More specifically, the SNPs of the following genes were explored:
ACE rs4353, rs4293, and rs4311 (chromosome 17), ADRβ2rs1042717 (chromosome 5), NOS3
rs1007311 and rs891512 (chromosome 7), IGF-1 rs2288378 and rs11111272 (chromosome 12),
36

IL6 rs2069845 and rs1554606 (chromosome 7) and APOE rs7412 (chromosome19). Each of
these polymorphisms are present in different frequencies in a gene, and have all been identified
as valid single nucleotide polymorphism for the target sample population.
Statistical Analysis
Means and standard deviations were calculated for all data. Allele frequencies were
calculated from genetic data. ANOVAs were used to assess the main effect of genotype, the
main effect of moderate-to-vigorous physical activity, and the interaction of the two variables on
fitness. An alpha level of 0.05 was used to determine significance, and an alpha value of 0.10
was set to determine a significant trend.
Results
Subject Characteristics
A total of 30 pre-pubertal, African American, obese subjects participated in the study.
Descriptive characteristics of these subjects are given in Table 2. All anthropometric data were
significantly less in girls than in boys, except BMI percentile, which was not significantly
different between the two groups.
Table 2: Mean Anthropometric Data of Girls, Boys, and Total Group (mean±SD)
Variable
Girls (n = 15)
Boys (n = 15)
Total (n = 30)
Age

8.7 ± 0.8

10.4 ± 2.0*

9.5 ± 1.7

Height (cm)

135.7 ± 6.9

148.5 ± 15.5*

141.9 ± 13.4

Weight (kg)

54.0 ± 8.1

75.8 ± 23.6*

64.5 ± 20.3

BMI (kg/m2)

29.3 ± 3.6

33.5 ± 6.8*

31.3 ± 5.7

BMI %ile

99.2 ± 0.5

99.2 ± 0.4

99.2 ± 0.4

81.4 ± 7.5
93.1 ± 17.1*
Waist Circ. (cm)
* denotes significant differences between girls and boys (P < 0.05)
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87.1 ± 14.1

Genotypes
The allele frequencies of the sample compared to the general population for each
individual candidate gene are reported in Table 3. The genotype frequencies for each SNP are
included in Table 4.
Physical Activity Assessment
All subjects were asked to wear a physical activity monitor (Actigraph GT3X) for seven
consecutive days following the lab visit. The mean minutes of wear time per day was 699
minutes. The mean number of minutes spent in each activity intensity is included in Table 5.
There was a significant difference in minutes of moderate activity accumulated daily in girls
compared to boys. The percentage of time spent in various activity intensities is shown in Table
6.
Table 3: Allele Frequency for All Genes in Sample Population and General African American
Population98
Allele

Sample
(%)

General
(%)

Gene

rs4353

G

45

41

IL6

rs4293

A
A

55
15

59
27

rs4311

G
T

85
32

73
30

rs1042717

C
A

68
34

70
39

G

66

61

Gene
ACE
ACE
ACE
ADRB2
NOS3

rs1007311

A
G

42
58

38
62

NOS3

rs891512

A
G

2
98

5
95

IL6
IGF-1
IGF-1
APOE
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Allele

Sample
(%)

General
(%)

rs2069845

G

29

33

rs1554606

A
T

77
29

68
33

rs2288378

G
T

71
26

67
17

rs11111272

C
G

74
44

83
36

C

56

64

T
C

11
89

13
87

rs7412

Table 4: Genotype Distribution and Frequency of Total Sample
Gene

SNP

Genotype

Total

Frequency

Gene

SNP

Genotype

Total

Frequency

ACE

rs4353

GG

6

20

IL6

rs2069845

GG/GA

18

60

GA

15

50

AA

12

40

AA

9

30

GA/AA

8

26.7

TT/TG

16

53.3

GG

22

73.3

GG

14

46.7

TT/TC

18

60

TT/TC

14

46.7

CC

12

40

CC

16

53.3

AA/GA

16

53.3

GG

5

16.7

GG

14

46.7

GC

16

53.3

AA

6

20

CC

9

30

GA

13

43.3

TT/TC

6

20

GG

11

36.7

CC

24

80

GA/AA
GG

1
29

3.3
96.7

ACE
ACE
ADR
B2
NOS3

NOS3

rs4293
rs4311

rs1042717
rs1007311

rs891512

IL6
IGF-1

IGF-1

APOE

rs1554606
rs2288378

rs11111272

rs7412

Table 5: Mean Daily Time Spent in Various Activities for Girls, Boys, and
Total Group (mean±SD)
Time Spent in
Activity
Girls (n = 15)
Boys (n = 15)
Total (n = 30)
384.9 ± 65.8
439.9 ± 121.1
412.4 ± 99.7
Sedentary
237.3 ± 46.6
224.5 ± 53.5
230.1 ± 49.7
Light
56.0 ± 27.5
36.1 ± 20.1
46.1 ± 25.7
Moderate
5.8 ± 3.3
4.2 ± 5.3
5.0 ± 4.4
Vigorous
61.7 ± 30.1
40.3 ± 24.0
51.0 ± 28.9
MVPA
683.9 ± 117.2
713.6 ± 126.9
698.8 ± 121.0
Wear Time
* denotes significant differences between boys and girls (P < 0.05)
Table 6: Mean Daily Time Spent in Various Activities for Girls, Boys, and
Total Group
Time Spent in
Activity
Sedentary
Light
Moderate
Vigorous
MVPA

Girls (n = 15)
56%
35%
8%
1%
9%

Boys (n = 15)
62%
32%
5%
1%
6%
39

Total (n = 30)
59%
33%
7%
1%
8%

Peak Oxygen Uptake
Physiological data during rest and for oxygen uptake are included in Table 7. There
were no significant differences in resting variables between girls and boys, except in diastolic
blood pressure. For VO2peak, there was a significant difference in absolute VO2peak (L·min-1),
indicating that girls had lower oxygen uptake than boys. Girls also had a lower respiratory
exchange ratio (RERpeak) compared to boys. VO2peak measures grouped by genotype are included
in Table 8. There were no significant differences in VO2peak, HRpeak, RERpeak, RPE, test time, and
peak MET level across genotypes.
Table 7: Mean Physiological Data for Girls, Boys, and Total Group (mean±SD)
Variable
Girls (n = 15)
Boys (n = 15)
Total (n = 30)
% Fat
Resting Heart Rate
(bpm)
Resting Systolic BP
(mm/Hg)
Resting Diastolic BP
(mm/Hg)

43.2 ± 4.1

40.9 ± 4.7

42.1 ± 4.5

75 ± 10.5

79 ± 9

77 ± 10

106 ± 12

113 ± 11

109 ± 12

58 ± 8

65 ± 9*

61 ± 9

Peak Heart Rate (bpm)

174 ± 16

179 ± 14

176 ± 15

RER

1.01 ± 0.06

1.07 ± 0.09*

1.04 ± 0.08

RPE

8±2

8±2

8±2

Test Length (min)

9.0 ± 2.7

8.8 ± 1.8

8.7 ± 2.2

Peak MET Value

6.3 ± 2.4

6.7 ± 1.3

6.5 ± 1.9

VO2peak (L/min)

1.06 ± 0.03

1.61 ± 0.06*

1.31 ± 0.08

VO2peak (ml/kg/min)

19.6 ± 4.8

22.7 ± 7.2

21.1 ± 6.0

35.9 ± 8.9
38.7 ± 11.6
VO2peak (ml/kgFFM/min)
* denotes significant differences between girls and boys (P < 0.05)
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37.2 ± 10.2

Table 8: Mean VO2peak Measures (mean ± SE) by Genotype (mean±SD)
Gene

SNP

Genotype

n

ACE

rs4353

AA

9

GA

15

GG

6

GA

8

GG

22

AA

--

TT/TC

18

CC

12

AA/GA

16

GG

14

ACE

41

ACE

ADRβ2

NOS3

NOS3

rs4293

rs4311

rs1042717

rs1007311

rs891512

AA

16

GA

13

GG

11

AA/GA

1

GG

29

VO2peak
(L·min-1)
1300.4 ±
397.2
1361.8 ±
646.3
1286.8 ±
535.0
1330.1 ±
195.7
1327.8 ±
118.0
1393.1 ±
129.0
1231.4 ±
158.0
1305.8 ±
138.2
1354.3 ±
147.8

1329.3 ±
229.5
1365.8 ±
155.9
1283.7 ±
169.5
1218.0 ±
553.0
1332.2 ±
102.7

VO2peak
(mL·kg1·min-1)

VO2peak
(mL·kgFFM1·min-1)

Gene

SNP

Genotype

n

20.2 ± 2.1

37.0 ± 3.5

IL6

rs2069845

GG/GA

18

20.9 ± 1.6

36.7 ± 2.7

AA

12

23.6 ± 2.5

39.9 ± 4.2

20.0 ± 2.2

35.4 ± 3.6

TT/TG

16

21.7 ± 1.3

38.2 ± 2.2

GG

14

20.9 ± 1.5

37.3 ± 2.4

TT/TC

14

21.7 ± 1.8

37.6 ± 3.0

CC

16

19.8 ± 1.5

34.5 ± 2.4

CC

9

22.9 ± 1.6

40.7 ± 2.6

GC

16

GG

5

TT/TC

6

CC

24

23.5 ± 2.5

41.0 ± 4.2

20.5 ± 1.7

36.2 ± 2.8

20.9 ± 1.9

36.9 ± 3.1

17.1 ± 6.2

31.9 ± 10.2

21.4 ± 1.1

37.6 ± 1.9

IL6

IGF-1

IGF-1

APOE

rs1554606

rs2288378

rs11111272

rs7412

VO2peak
(L·min-1)
1185.9 ±
147.8
1542.1 ±
151.0

1231.9 ±
135.8
1438.6 ±
145.1
1312.2 ±
147.8
1342.6 ±
138.3
1541.4 ±
178.3
1300.2 ±
133.7
1035.2 ±
239.2
1315.0 ±
225.9
1331.8 ±
113.0

VO2peak
(mL·kg1·min-1)

VO2peak
(mL·kgFFM1·min-1)

19.7 ± 1.4

36.4 ± 2.4

23.5 ± 1.7

39.0 ± 2.9

20.7 ± 1.5

37.5 ± 2.6

21.9 ± 1.7

37.3 ± 2.7

22.3 ± 1.6

39.7 ± 2.7

20.3 ± 1.5

35.4 ± 2.5

19.8 ± 2.1

36.6 ± 3.4

22.1 ± 1.6

38.7 ± 2.6

21.0 ± 2.8

34.8 ± 4.6

18.3 ± 2.5

32.6 ± 4.1

22.0 ± 1.2

38.6 ± 2.0

Results of the one-way ANOVAs indicated there were no significant associations
between genotype and VO2peak (ml·kgFFM-1·min-1) for any of the candidate genes (Table 8). There
were trends towards significance for the IL6 rs2069845 gene for absolute and relative VO2peak
measures (P = 0.078, and P = 0.094, respectively). There was also a trend toward significance for
the ADRβ2 rs1042717 gene for leanVO2peak (P = 0.092). These trends were determined as an
alpha value between 0.05 and 0.10. ANOVA source tables are shown in Appendix F.

Discussion
The purpose of this study was to determine the association of genotype and aerobic
fitness, and the interaction of genotype and physical activity on aerobic fitness. The current study
revealed no association of genotype and no gene-activity interaction effect on fitness.
The study is unique to the literature because of the use of objectively monitored physical
activity and measured peak aerobic fitness levels. Previous literature has identified potential
associations of the candidate genes ACE, ADRB2, NOS3, IL6, IGF-1 and APO-E with fitness
levels in adults; however the results of the current study are equivocal. Furthermore, few studies
have focused on children, and even less has been done assessing the gene-activity interaction
effect of fitness levels in children.
It was hypothesized that there would be a significant association of the genotype on
VO2peak. The results demonstrate no association of any candidate gene with VO2peak, and this
finding has been demonstrated previously in adult literature and in the limited research in
children. The second hypothesis was that there would be a significant interaction effect between
the genotype and activity level on VO2peak. Again, this finding was insignificant, and consistent
with the small body of literature published assessing the gene-activity interaction on fitness in
adults and children.
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However, the results of the study did show interesting findings in the genotype
frequencies. Although the allele frequencies are comparable to the general African American
population, some of the SNPs have an underrepresentation of genotypes in the sample.
Specifically, in the ACE gene, SNP rs4293 the AA genotype is absent, and in the NOS3 SNP
rs891512, the GG genotype was absent. Although this has not been previously shown in these
SNPs, it is possible that there is a clustering effect of specific genotypes in the pre-pubertal,
African American, obese population. This may indicate a predisposition to lower fitness and
increased weight status based on the genotype, however, due to the limited number subjects, this
is difficult to conclude.
Regardless, the lack of association and interaction effects found, in previous studies and
the current study, emphasize the importance behavioral determinants of fitness, including
physical activity and lifestyle. As mentioned previously, body composition, racial differences,
maturation, and activity may all impact the fitness level of a child. The current study identifies
the demographic, physiological, and physical activity level profile on the subjects that may aide
in future understanding of an individual’s environment and its contribution to fitness.
Obese children are significantly less physically active compared to their normal weight
counterparts.99 Although these data had no normal weight comparison group, it is evident from
the data included in Table 5 that subjects were not meeting the recommended 60 minutes of
moderate to vigorous physical activity guideline for children. A study by Trost et al.99 assessed
non-obese and obese children and found that on average, the obese children spent approximately
63 min·day-1 in moderate intensity activity, and 7 min·day-1 in vigorous intensity activity. The
total sample of the current study spent approximately 51 min·day,-1 however the time spent in
vigorous intensity activity is roughly the same as reported in Trost’s study (Table 5). This low
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accumulation of time in vigorous intensity activity may partially explain the results of the peak
exercise test. As shown in Table 7, at peak exercise, the children barely reached a MET value
that could be deemed a vigorous intensity (> 6 METs). Therefore, this low accumulation of
vigorous intensity activity may be as a result of the children’s inability to physiologically sustain
a MET value greater than 6.0 METs. Since our subjects’ METpeak during the exercise test was
6.6 ± 1.9 METs, it would be expected that very few children are accumulating much vigorous
activity, and that a majority of their time is spent in sedentary, light or moderate activity.
The literature has also shown that boys are more active than girls, and results of this
study demonstrate the opposite. There are a number of potential reasons for the significantly
higher accumulated minutes of moderate and moderate-to-vigorous activity in girls. The girls
included in this study were significantly younger than the boys (8.6 ± 1.0 years vs. 10.5 ± 1.9
years) and they were also lighter in weight and had a lower percent fat compared to the boys.
The younger age of the girls may impact the activity levels because they are engaging in more
active play outside, instead of participating in sedentary activities, and being lighter may allow
for the girls to be more active by not limiting what types of activities or intensities they want to
participate in during the day.
There are many strengths of this study. The homogenous nature of the sample population
allowed for a number of different factors, including pubertal status, weight status and race to be
controlled for in the study. The use of objective monitoring of physical activity is an important
strength of the study because the accelerometer data allows for a valid and accurate
representation of the subject’s habitual physical activity, including intensity and duration of each
subject’s physical activity. In addition, the subjects averaged approximately 699 minutes of
wear time a day, which allowed for an accurate assessment of daily activity. The use of a
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maximal, graded exercise test allowed for peak exercise values to be obtained for an accurate
assessment of fitness.
A major limitation of this study is the small sample size. The 30 subjects included in the
analysis may not allow for an accurate representation of the activity levels or genetic associations
on fitness of children of a similar age. Previous association and interaction studies have
suggested that samples include in excess for 200 subjects in order to ascertain the statistical
power in order to draw an accurate conclusion. Unfortunately, for this study, it was necessary
for the physicians at the clinics to recruit the participants and as a result, the appropriate sample
size was not able to be obtained. Future studies should include a site near the campus that allows
for study investigators to take on the primary role of study recruiter during the study in order to
avoid issues with subject recruitment.
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CHAPTER 4: CONCLUSIONS
The main objectives of this study were to assess the association of genotype with aerobic
fitness, and secondly to assess the interaction effect of genotype and physical activity on aerobic
fitness in children. This study found no significant association of genotype and fitness level, and
no interaction effect of candidate gene and activity level on aerobic fitness in pre-pubertal,
African-American, obese children. Future studies should continue to use objective measures of
physical activity and measured aerobic fitness on a larger, more diverse sample in order to
further assess associations of genotype, activity levels, and fitness in children.
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Parental or Legal Guardian Permission for Child to Act as a Subject in a Research Study
The association of certain genotypes and obesity-related disorders in pre-pubertal Black youth
Co-Principal Investigators: Dawn P. Coe, Ph.D., Assistant Professor
Department of Exercise, Sport, and Leisure Studies
338 HPER
1914 Andy Holt Avenue
Knoxville, TN 37996
(865)974-0294
Bruce Alpert, M.D., Professor
Plough Foundation Chair of Excellence
Department of Pediatrics (Cardiology)
215 Le Bonheur Physicians Office Building
777 Washington Avenue
Memphis, TN 38105
(901) 287-6380
Co-Investigator:

Cheryl J. Kojima, Ph.D., Associate Professor
Naima Moustaid-Moussa, Ph.D., Professor
Dixie L. Thompson, Ph.D, Professor
Jennifer I. Flynn, B.S.

1. INTRODUCTION:
In this permission form, the word “you” means you and/or your child.
You/your child are being given the opportunity to participate in this study because you have not
yet experienced puberty (when the sex organs mature), are African American and considered to
be obese (very overweight). You are being given an opportunity to donate a sample, using a
cheek swab, to this research study for genetic analysis. Your participation in this research study
is voluntary. Please read this permission form carefully and take your time making your
decision. As the study staff discusses this permission form with you, please ask him/her to
explain any words or information that you do not clearly understand. We encourage you to talk
with your family and friends before you decide to take part in this research study. The nature of
the study, risks, inconveniences, discomforts, and other important information about the study are
listed below.
Please tell the study doctor or study staff if you are taking part in another research study.
The purpose of this study is to find out whether your genes increase your chance for gaining
weight, and having problems that may be caused by weight gain (high blood sugar, high blood
pressure, and heart problems). Genes are like blueprints in each of our cells that determine traits
that we inherit, like eye color and hair color. Genes may also influence what diseases we get and
how we respond to treatment. DNA is the substance that makes up our genes.
This is a single center study and approximately 100 subjects will be participating in this study.
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The study will take place at the University of Tennessee Applied Physiology Laboratory
(UTAPL) located at 1914 Andy Holt, Room 309 HPER, Knoxville, TN 37996.
Your participation in this study will last approximately seven days. One and a half hours (1 ½
hours – one visit only) will be spent at the UTAPL and then you will be asked to wear an activity
monitor (explained later in this form) for seven days.
2. PROCEDURES TO BE FOLLOWED:
If you choose to participate in this research, samples will be taken from your mouth. These
samples will be used for the extraction of DNA. You will also be asked to have three (3)
assessments completed as part of the study. Body composition (body fat and lean muscle mass)
will be assessed using Dual Energy X-Ray Absorptiometry (DEXA) and waist measurement,
fitness level (how much exercise you can handle at one time) will be assessed during a cycle
exercise test using a stationary cycle, and activity will be measured using a physical activity
monitor. These assessments will all take place at the UTAPL and will be performed for research
purposes only.
Genetic Sample
You will be asked to donate a tissue sample from your mouth for genetic analysis. You will rinse
out your mouth with water and a nurse/research assistant will collect tissue by rubbing a small
brush on the inside of you cheek, approximately 20 times on each side. The DNA specimen, the
data associated with the specimen, data generated from analysis of the specimen will be owned
by the sponsor of this research study, the University of Tennessee. Your DNA sample will be
retained until the study is completed (approximately 12 months). The University of Tennessee
will have ownership of the genetic sample. No profit making activities will result from the
research use of the sample. Results of the genetic analyses are not relevant to your health and
therefore will not be shared with you. Once the genetic sample has been analyzed and the
protocol is completed, your sample will no longer be needed and will be destroyed. We will hold
on to your data until full analyses are complete, for approximately one year, and you will not be
re-contacted to take part in the study in the future.
DEXA
The DEXA scan is able to determine the amount of fat and lean mass (bone, organs, and muscle)
that makes up your body. For the DEXA assessment, you will be asked to lie still on a padded
table while the machine scans your body. A whole body scan takes between 10 – 20 minutes.
This x-ray scan takes pictures of your body and from these pictures we can tell how much fat and
lean mass (bone, organs, muscle) make up your body.
Waist Measurement
A tape measure will be used to measure the distance around your waist.
Cycle Test
The purpose of this test is to determine your fitness level. This will be done by performing an
exercise test on a cycle that gradually becomes more difficult. Prior to the test, height, weight and
blood pressure will be measured. The pedal rate, how fast the pedals are moving, will remain the
same throughout the test and every two minutes resistance, how hard it is to pedal, will be added
to make the test a little more difficult. The test will end when you request to stop or when you

57

are no longer able to pedal at a certain speed. You may request to stop the test at any time.
During the test, heart rate will be monitored using strap around your chest and you will wear a
mask covering your mouth and nose to assess how much oxygen your body is using to make
energy. Although your mouth and nose are covered with the mask you will still be able to talk
during the test. The more oxygen you can use the higher fitness level you have. You will also be
asked how hard you feel you are working during the test using a 0-10 rating of perceived exertion
(RPE) scale. If you develop any pain or have any abnormal response to the exercise test, the test
will immediately be stopped. If you wish to stop the test at any time, you can either ask for the
test to stop or just stop pedaling.
Physical Activity Monitoring
You will be asked to wear a monitor to assess physical activity levels. This device is a small box,
the size of a small pager that will be worn on a belt around the waist. The device will be worn
for one week and you will wear the monitor at all times except during water activities
(swimming, bathing, showering) and when you are sleeping. At the end of the week, you will
mail the monitor to the study center using a self-addressed stamped box (provided by the
researchers).
The DNA specimen, the data associated with the specimen, data generated from analysis of the
specimen will be owned by the sponsor of this research study, the University of Tennessee. Your
DNA sample will be retained until the study is completed (approximately 12 months). The
University of Tennessee will have ownership of the genetic sample. No profit making activities
will result from the research use of the sample. Results of the genetic analyses are not relevant to
your health and therefore will not be shared with you. Once the genetic sample has been
analyzed and the protocol is completed, your sample will no longer be needed and will be
destroyed. We will hold on to your data until full analyses are complete, for approximately one
year, and you will not be re-contacted to take part in the study in the future.
The following information will be collected from your medical record: date of birth, maturity status, a
list of your current medications, and the results from the blood sample drawn in the clinic. This
information will be collected from the medical chart because these procedures will have already been
done during a standard care clinic visit, and will not need to be repeated. All of the other procedures
in the study, including the collection of the genetic sample, the DEXA scan, cycle test, waist
measurement, and activity monitoring, are being performed for research purposes only.

3. RISKS ASSOCIATED WITH PARTICIPATION:
Every effort will be made to minimize any discomforts or risks.
There are potential risks associated with an exercise test that may include lightheadedness, chest
discomfort, leg cramps, falling, muscle sprain/strain, and abnormal blood pressure. The risk of
these problems is rare (1-5% chance). Additionally, there are some very rare (<1%) risks that
include: irregular heart rates/rhythms, heart attack, stroke or death. Personnel trained in pediatric
CPR, will be available to take care of these situations and emergency equipment will be readily
available at all times.
There are only minor risks associated with the DEXA scan. It may feel uncomfortable, as you
have to lie on an open table for 12-20 minutes as the DEXA scans your body. The amount of
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radiation to which you will be exposed is 1/20th of what you would receive from a chest x-ray or
about the same amount of radiation received during an airline trip from New York to Los
Angeles.
There is minimal risk associated with the heart rate and physical activity monitors. The belts,
worn around the chest and waist that contain the device may rub on the skin, causing irritation.
There is a potential risk of unintended disclosure of confidential information to parties outside
the research context that might affect your ability to get insurance or a job. However, these risks
are quite remote since appropriate confidentiality measures will be taken to protect any
information about your health that is revealed by your DNA sample.
4. BENEFITS ASSOCIATED WITH PARTICIPATION:
There are no direct benefits to you for participating in this research study. Your participation in
this research study may provide additional information regarding the possible causes of obesity
and obesity-related disorders in children.
5. ALTERNATIVES TO PARTICIPATION:
An alternative to participating in this study is to not participate in the study. You will receive the
same medical care whether or not you participate in this research study.
6. CONFIDENTIALITY:
All of your paper research records will be stored in locked file cabinets and will be accessible
only to research personnel.
All of your electronic research records will be computer password protected and accessible only
to research personnel.
Your DNAsample will be maintained at the University of Tennessee, Knoxville campus during
the study and will be labeled with a code.
Your research records and your DNA sample will be transmitted to the University of Tennessee,
Knoxville campus and will be labeled with a code. A master key that links your name with the
code on your research record and specimen will be maintained at the local investigative site
(UTAPL).
Under federal privacy regulations, you have the right to determine who has access to your
personal health information (called “protected health information” or PHI). PHI collected in this
study may include your medical history, the results of physical exams, lab tests, x-ray exams, and
other diagnostic and treatment procedures, as well as basic demographic information. By signing
this permission form, you are authorizing the researchers at the University of Tennessee to have
access to your PHI collected in this studyand to receive your PHI from your physician and
facilities where you have received health care. The Institutional Review Board (IRB) at the
University of Tennessee may review your PHI as part of its responsibility to protect the rights
and welfare of research subjects. Your PHI will not be used or disclosed to any other person or
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entity, except as required by law, or for authorized oversight of this research study by other
regulatory agencies, or for other research for which the use and disclosure of your PHI has been
approved by the IRB. Your PHI will be used only for the research purposes described in the
Introduction of this permission form. Your PHI will be used until the study is completed.
You may cancel this authorization in writing or by phone at any time by contacting the principal
investigator listed on the first page of the permission form. If you cancel the authorization,
continued use of your PHI is permitted if it was obtained before the cancellation and its use is
necessary in completing the research. However, PHI collected after your cancellation may not be
used in the study. If you refuse to provide this authorization, you will not be able to participate in
the research study. If you cancel the authorization, then you will be withdrawn from the study.
Finally, the federal regulations allow you to obtain access to your PHI collected or used in this
study.
Information about your participation in this study will be placed in your medical record; as such,
this information could be made available to your employer or insurer.
You will not be identified in any presentations or publications based on the results of the research
study.
7. COMPENSATION AND TREATMENT FOR INJURY:
You are not waiving any legal rights or releasing the University of Tennessee, or its agents, from
liability for negligence. In the event of physical injury resulting from research procedures, the
University of Tennessee has not budgeted funds for compensation either for lost wages or for
medical treatment. Therefore, the University of Tennessee does not provide for treatment or
reimbursement for such injuries. No compensation will be available for any ancillary expenses
incurred as a result of research related physical injuries, additional hospital bills, lost wages,
travel expenses, etc.
If you suffer a research-related injury, your study nurse will provide acute medical treatment and
will provide you with a subsequent referral to appropriate health care facilities.
You and/or your insurance carrier will be billed for the costs associated with the medical
treatment of a research-related injury.
Additionally, no compensation will be available to subjects for any non-physical injuries that
may be incurred as a result of research participation, such as exposure to criminal or civil
liability, or damage to their reputation, financial standing, or employability

8. QUESTIONS:
If you have any questions about this study, you may contact Dawn P. Coe, Ph.D.at 865-974-0294
You may contact the ETCH IRB Chairman, at 865-541-8477 if you have any questions about
your rights as a participant in this study or your rights as a research subject.
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9. PAYMENT FOR PARTICIPATION:
You (the child) will receive a $25.00 gift card to Toys R Us and you (the parent/legally authorized
representative) will receive a $10 gas card for volunteering your time to be a part of this study when
the physical activity monitor is returned to the researchers.

10. COSTS OF PARTICIPATION:
There is no cost to you to participate in this study.
11. VOLUNTARY PARTICIPATION:
Your participation in this research study is completely voluntary. You may choose not to
participate or to drop out of the study without any penalty or loss of benefits to which you are
otherwise entitled.
If you give your permission to Dr. Coe to use your DNA sample for the research specified above,
and then you decide later, once the specimen has been collected, that you do not want the
specimen to be used, you may contact Dr. Coe and indicate your wishes. If you withdraw from
this research study, your specimen (DNA) and related data will be destroyed; however, any
analysis that was completed before your child chooses to withdraw from the research study will
be retained if it is necessary for completion of the research.
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12. PERMISSION OF SUBJECT:
You have read or have had read to you a description of the research study as outlined above. The
investigator or his/her representative has explained the research study to you and has answered
all the questions you have at this time. You knowingly and freely choose to allow your child to
participate in the research study. A copy of this permission form will be given to you for your
records.
_
______________________________________
Signature of Research Subject

____________ ______
Date
Time

_______________________________________
Printed Name of Research Subject
________________________________________
Signature of Person Obtaining Permission

____________________
Date
Time

________________________________________
Printed Name of Person Obtaining Permission
In my judgment, the subject or the legally authorized representative has voluntarily and
knowingly given permission and possesses the legal capacity to give permission to participate in
this research study.

__________________________________________
Signature of Investigator

____________ ______
Date
Time

__________________________________________
Signature of Legally Authorized Representative

____________ _____
Date
Time

__________________________________________
Relationship of Legally Authorized Representative
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The association of certain genotypes and obesity-related disorders in pre-pubertal Black youth
The assent discussion was initiated on ______________(date) at __________ (time).
The information was presented in age-appropriate terms.
The minor: _______________________________________________(Subject’s Name)
Agreed to take part in the study on _________________(date) at _______________ (time).
Declined to take part in the study. The minor declined for the following reason(s):

An assent discussion was not initiated with the minor for the following reason(s):
Minor is under 8 years of age
Minor is physically incapacitated
Minor is cognitively or emotionally unable to participate in an assent discussion
Minor refused to take part in the discussion
Other_________________________________________________________
RESEARCHER/DESIGNEE STATEMENT: I hereby certify that I have discussed the research
project with the research participant and/or his/her parent(s) or legal guardian(s). I have explained all
the information contained in the permission document, including any risks that may be reasonably
expected to occur. I further certify that the research participant was encouraged to ask questions and
that all questions were answered.

______________________________
Researcher/Designee Printed Name

______________________________ ________________
Researcher/Designee Signature
Date

_______________
Time (AM/PM)

______________________________
Minor Subject Printed Name
OPTIONAL
________________________________
Minor Subject Signature (8-13 years)
OPTIONAL

__________________
Date
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________________
Time (AM/PM)

APPENDIX B:
Parental Informed Consent and Subject Assent Form for Memphis, TN
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The association of certain genotypes and obesity-related disorders in pre-pubertal Black youth
Principal Investigator:

Dawn P. Coe, Ph.D., Assistant Professor
Department of Exercise, Sport, and Leisure Studies
338 HPER
1914 Andy Holt Avenue
Knoxville, TN 37996
(865)974-0294
Bruce Alpert, M.D., Professor
Plough Foundation Chair of Excellence
Department of Pediatrics (Cardiology)
215 Le Bonheur Physicians Office Building
777 Washington Avenue
Memphis, TN 38105
(901) 287-6380

Co-Investigator:

Cheryl J. Kojima, Ph.D., Associate Professor
Naima Moustaid-Moussa, Ph.D., Professor
Dixie L. Thompson, Ph.D, Professor
Pedro Velasquez, M.D.
Nicole Barnes, M.D.
Claudia P. Neira, DNP, FNP
Jennifer I. Flynn, B.S.

1. INTRODUCTION:
In this consent form, the word “you” means you and/or your child.
You/your child are being given the opportunity to participate in this study because you have not
yet experienced puberty (when the sex organs mature), are African American and considered to
be obese (very overweight). You are being given an opportunity to donate a sample, using a
cheek swab, to this research study for genetic analysis. Your participation in this research study
is voluntary. Please read this consent form carefully and take your time making your decision.
As the study staff discusses this consent form with you, please ask him/her to explain any words
or information that you do not clearly understand. We encourage you to talk with your family and
friends before you decide to take part in this research study. The nature of the study, risks,
inconveniences, discomforts, and other important information about the study are listed below.
Please tell the study doctor or study staff if you are taking part in another research study.
The purpose of this study is to find out whether your genes increase your chance for gaining
weight, and having problems that may be caused by weight gain (high blood sugar, high blood
pressure, and heart problems). Genes are like blueprints in each of our cells that determine traits
that we inherit, like eye color and hair color. Genes may also influence what diseases we get and
how we respond to treatment. DNA is the substance that makes up our genes.
This is a single center study and approximately 100 subjects will be participating in this study.
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The study will take place at the Clinical and Translational Science Institute Clinical Research
Unit (CTSI/CRU) (1265 Union Ave, 8th Floor East Wing, Memphis, TN 38104).
Your participation in this study will last approximately seven days. One and a half hours (1 ½
hours – one visit only) will be spent at the CTSI/CRU and then you will be asked to wear an
activity monitor (explained later in this form) for seven days.
2. PROCEDURES TO BE FOLLOWED:
If you choose to participate in this research, samples will be taken from your mouth. These
samples will be used for the extraction of DNA. You will also be asked to have three (3)
assessments completed as part of the study. Body composition (body fat and lean muscle mass)
will be assessed using Dual Energy X-Ray Absorptiometry (DEXA) and waist measurement,
fitness level (how much exercise you can handle at one time) will be assessed during a cycle
exercise test using a stationary cycle, and activity will be measured using a physical activity
monitor. These assessments will all take place at the CTSI/CRU and will be performed for
research purposes only.
Genetic Sample
You will be asked to donate a tissue sample from your mouth for genetic analysis. You will rinse
out your mouth with water and a nurse/research assistant will collect tissue by rubbing a small
brush on the inside of you cheek, approximately 20 times on each side. The DNA specimen, the
data associated with the specimen, data generated from analysis of the specimen will be owned
by the sponsor of this research study, the University of Tennessee. Your DNA sample will be
retained until the study is completed (approximately 12 months). The University of Tennessee
will have ownership of the genetic sample. No profit making activities will result from the
research use of the sample. Results of the genetic analyses are not relevant to your health and
therefore will not be shared with you. Once the genetic sample has been analyzed and the
protocol is completed, your sample will no longer be needed and will be destroyed. We will hold
on to your data until full analyses are complete, for approximately one year, and you will not be
re-contacted to take part in the study in the future.
DEXA
The DEXA scan is able to determine the amount of fat and lean mass (bone, organs, muscle) that
makes up your body. For the DEXA assessment, you will be asked to lie still on a padded table
while the machine scans your body. A whole body scan takes between 10 – 20 minutes. This xray scan takes pictures of your body and from these pictures we can tell how much fat and lean
mass (bone, organs, muscle) make up your body.
Waist Measurement
A tape measure will be used to measure the distance around your waist.

Cycle Test
The purpose of this test is to determine your fitness level. This will be done by performing an
exercise test on a cycle that gradually becomes more difficult. Prior to the test, height, weight and
blood pressure will be measured. The pedal rate, how fast the pedals are moving, will remain the
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same throughout the test and every two minutes resistance, how hard it is to pedal, will be added
to make the test a little more difficult. The test will end when you request to stop or when you
are no longer able to pedal at a certain speed. You may request to stop the test at any time.
During the test, heart rate will be monitored using strap around your chest and you will wear a
mask covering your mouth and nose to assess how much oxygen your body is using to make
energy. Although your mouth and nose are covered with the mask you will still be able to talk
during the test. The more oxygen you can use the higher fitness level you have. You will also be
asked how hard you feel you are working during the test using a 0-10 rating of perceived exertion
(RPE) scale. If you develop any pain or have any abnormal response to the exercise test, the test
will immediately be stopped. If you wish to stop the test at any time, you can either ask for the
test to stop or just stop pedaling.
Physical Activity Monitoring
You will be asked to wear a monitor to assess physical activity levels. This device is a small box,
the size of a small pager that will be worn on a belt around the waist. The device will be worn
for one week and you will wear the monitor at all times except during water activities
(swimming, bathing, showering) and when you are sleeping. At the end of the week, you will
mail the monitor to the study center using a self-addressed stamped padded envelope (provided
by the researchers).
The DNA specimen, the data associated with the specimen, data generated from analysis of the
specimen will be owned by the sponsor of this research study, the University of Tennessee. Your
DNA sample will be retained until the study is completed (approximately 12 months). The
University of Tennessee will have ownership of the genetic sample. No profit making activities
will result from the research use of the sample. Results of the genetic analyses are not relevant to
your health and therefore will not be shared with you. Once the genetic sample has been
analyzed and the protocol is completed, your sample will no longer be needed and will be
destroyed. We will hold on to your data until full analyses are complete, for approximately one
year, and you will not be re-contacted to take part in the study in the future.
The following information will be collected from your medical record: date of birth, maturity status, a
list of your current medications, and the results from the blood sample drawn in the clinic. This
information will be collected from the medical chart because these procedures will have already been
done during a standard care clinic visit, and will not need to be repeated. All of the other procedures
in the study, including the collection of the genetic sample, the DEXA scan, cycle test, waist
measurement, and activity monitoring, are being performed for research purposes only.

3. RISKS ASSOCIATED WITH PARTICIPATION:
Every effort will be made to minimize any discomforts or risks.
There are potential risks associated with an exercise test that may include lightheadedness, chest
discomfort, leg cramps, falling, muscle sprain/strain, and abnormal blood pressure. The risk of
these problems is rare (1-5% chance). Additionally, there are some very rare (<1%) risks that
include: irregular heart rates/rhythms, heart attack, stroke or death. Personnel trained in pediatric
CPR, will be available to take care of these situations and emergency equipment will be readily
available at all times.
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There are only minor risks associated with the DEXA scan. It may feel uncomfortable, as you
have to lie on an open table for 12-20 minutes as the DEXA scans your body. The total amount
of radiation you will receive in this study is about the same as you would receive from
exposure to about one day of natural sources of radiation (about one mrem).
There is minimal risk associated with the heart rate and physical activity monitors. The belts,
worn around the chest and waist that contain the device may rub on the skin, causing irritation.
There is a potential risk of unintended disclosure of confidential information to parties outside
the research context that might affect your ability to get insurance or a job. However, these risks
are quite remote since appropriate confidentiality measures will be taken to protect any
information about your health that is revealed by your DNA sample.
4. BENEFITS ASSOCIATED WITH PARTICIPATION:
There are no direct benefits to you for participating in this research study. Your participation in
this research study may provide additional information regarding the possible causes of obesity
and obesity-related disorders in children.
5. ALTERNATIVES TO PARTICIPATION:
An alternative to participating in this study is to not participate in the study. You will receive the
same medical care whether or not you participate in this research study.
6. CONFIDENTIALITY:
All of your paper research records will be stored in locked file cabinets and will be accessible
only to research personnel.
All of your electronic research records will be computer password protected and accessible only
to research personnel.
Your DNAsample will be maintained at the University of Tennessee, Knoxville campus during
the study and will be labeled with a code.
Your research records and your DNA sample will be transmitted to the University of Tennessee,
Knoxville campus and will be labeled with a code. A master key that links your name with the
code on your research record and specimen will be maintained at the local investigative site
(CTSI/CRU in Memphis, TN).
Under federal privacy regulations, you have the right to determine who has access to your
personal health information (called “protected health information” or PHI). PHI collected in this
study may include your medical history, the results of physical exams, lab tests, x-ray exams, and
other diagnostic and treatment procedures, as well as basic demographic information. By signing
this consent form, you are authorizing the researchers at the University of Tennessee to have
access to your PHI collected in this study and to receive your PHI from your physician and
facilities where you have received health care. The Institutional Review Board (IRB) at the
University of Tennessee Health Science Center may review your PHI as part of its responsibility
to protect the rights and welfare of research subjects. Your PHI will not be used or disclosed to
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any other person or entity, except as required by law, or for authorized oversight of this research
study by other regulatory agencies, or for other research for which the use and disclosure of your
PHI has been approved by the IRB. Your PHI will be used only for the research purposes
described in the Introduction of this consent form. Your PHI will be used until the study is
completed.
You may cancel this authorization in writing or by phone at any time by contacting the principal
investigator listed on the first page of the consent form. If you cancel the authorization,
continued use of your PHI is permitted if it was obtained before the cancellation and its use is
necessary in completing the research. However, PHI collected after your cancellation may not be
used in the study. If you refuse to provide this authorization, you will not be able to participate in
the research study. If you cancel the authorization, then you will be withdrawn from the study.
Finally, the federal regulations allow you to obtain access to your PHI collected or used in this
study.
Information about your participation in this study will be placed in your medical record; as such,
this information could be made available to your employer or insurer.
You will not be identified in any presentations or publications based on the results of the research
study.
7. COMPENSATION AND TREATMENT FOR INJURY:
You are not waiving any legal rights or releasing the University of Tennessee or the LifeDOC
Clinic, or the agents of either, from liability for negligence. In the event of physical injury
resulting from research procedures, neither the University of Tennessee nor the LifeDOC Clinic
has funds budgeted for compensation either for lost wages or for medical treatment. Therefore,
neither the University of Tennessee nor the LifeDOC Clinic provides for treatment or
reimbursement for such injuries. No compensation will be available for any ancillary expenses
incurred as a result of research related physical injuries, additional hospital bills, lost wages,
travel expenses, etc.
If you suffer a research-related injury, your study nurse will provide acute medical treatment and
will provide you with a subsequent referral to appropriate health care facilities.
You and/or your insurance carrier will be billed for the costs associated with the medical
treatment of a research-related injury.
Additionally, no compensation will be available to subjects for any non-physical injuries that
may be incurred as a result of research participation, such as exposure to criminal or civil
liability, or damage to their reputation, financial standing, or employability
8. QUESTIONS:
If you have any questions about this study, you may contact Dawn P. Coe, Ph.D.at 865-974-0294
In the event of a research-related injury, contact Dr. Bruce Alpert at 901-287-6781. This
telephone number is an office number.
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You may contact Dr. Terrence F. Ackerman, Ph.D., UTHSC IRB Chairman, at 901-448-4824 if
you have any questions about your rights as a participant in this study or your rights as a research
subject.
9. PAYMENT FOR PARTICIPATION:
You (the child) will receive a $25.00gift card to Toys R Us and you (the parent/legally authorized
representative) will receive a $10 gas card for volunteering your time to be a part of this study when
the physical activity monitor is returned to the researchers.

10. COSTS OF PARTICIPATION:
There is no cost to you to participate in this study.
11. VOLUNTARY PARTICIPATION:
Your participation in this research study is completely voluntary. You may choose not to
participate or to drop out of the study without any penalty or loss of benefits to which you are
otherwise entitled.
If you give your permission to Dr. Coe to use your DNA sample for the research specified above,
and then you decide later, once the specimen has been collected, that you do not want the
specimen to be used, you may contact Dr. Coe and indicate your wishes. If you withdraw from
this research study, your specimen (DNA) and related data will be destroyed; however, any
analysis that was completed before your child chooses to withdraw from the research study will
be retained if it is necessary for completion of the research.

12. CONSENT OF SUBJECT:
You have read or have had read to you a description of the research study as outlined above. The
investigator or his/her representative has explained the research study to you and has answered
all the questions you have at this time. You knowingly and freely choose to allow your child to
participate in the research study. A copy of this consent form will be given to you for your
records.
_
______________________________________
Signature of Research Subject
_______________________________________
Printed Name of Research Subject
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____________ ______
Date

Time

________________________________________ ____________
Signature of Person Obtaining Consent
Date

______
Time

________________________________________
Printed Name of Person Obtaining Consent
In my judgment, the subject or the legally authorized representative has voluntarily and
knowingly given informed consent and possesses the legal capacity to give informed consent to
participate in this research study.

__________________________________________
Signature of Investigator
Date

____________ ______
Time

__________________________________________
Signature of Legally Authorized Representative

____________ _____
Date
Time

__________________________________________
Relationship of Legally Authorized Representative

The association of certain genotypes and obesity-related disorders in pre-pubertal Black youth
The assent discussion was initiated on ______________(date) at __________ (time).
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The information was presented in age-appropriate terms.
The minor: _______________________________________________(Subject’s Name)
Agreed to take part in the study on _________________(date) at _______________ (time).
Declined to take part in the study. The minor declined for the following reason(s):

An assent discussion was not initiated with the minor for the following reason(s):
Minor is under 8 years of age
Minor is physically incapacitated
Minor is cognitively or emotionally unable to participate in an assent discussion
Minor refused to take part in the discussion
Other_________________________________________________________

RESEARCHER/DESIGNEE STATEMENT: I hereby certify that I have discussed the research
project with the research participant and/or his/her parent(s) or legal guardian(s). I have explained all
the information contained in the informed consent document, including any risks that may be
reasonably expected to occur. I further certify that the research participant was encouraged to ask
questions and that all questions were answered.
______________________________
Researcher/Designee Printed Name

______________________________ ________________
Researcher/Designee Signature
Date

_______________
Time (AM/PM)

______________________________
Minor Subject Printed Name

________________________________
Minor Subject Signature (8-13 years)

__________________
Date
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________________
Time (AM/PM)

APPENDIX C:
RPE Scale
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Robertson, R. et al. Children’s OMNI Scale of Perceived Exertion: mixed gender and race validation.
Med Sci Sports Exerc. 2000;32:452-458.
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APPENDIX D:
SNP Assay Information
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Gene Name: ACE rs4353
Angiotensin I Converting Enzyme (peptidyl-dipeptidase A) 1
Assay ID: C____589818_10
Location: Chr. 17 – 61570422
Context Sequence (VIC/FAM):
CAGTTGTTTCCTTCAGGGAGCCTCC[A/G]TCTTGGGAGATAAAGCATGTGTAC
A
Polymorphism: A/G, Transition Substitution

1) Gene Name: ACE rs4293
Angiotensin I Converting Enzyme (peptidyl-dipeptidase A) 1;similar to TRIMCyp
Assay ID: C___1247701_10
Location: Chr. 17 - 61555666
Context Sequence (VIC/FAM):
GGGGAGTTACTTTCTGTTAAAGGAA[A/G]CATTCTGGAGTAGGAAGCCAAATT
C
Polymorphism: A/G, Transition Substitution

2) Gene Name: ACE rs4311
Angiotensin I Converting Enzyme (peptidyl-dipeptidase A) 1
Assay ID: C___1247707_1_
Location: Chr. 17 - 61560763
Context Sequence (VIC/FAM):
GGTGGAAATGCCTTTTCTACAAAAG[C/T]TAAATCCATCTGTTTGCAACCTCTA
Polymorphism: C/T, Transition Substitution

3) Gene Name: ADRβ2 rs1042717
Adrenergic, beta-2-, receptor, surface
Assay ID: C___2084766_10
Location: Chr. 5 - 148206646
Context Sequence (VIC/FAM):
CCTGTGCTGATCTGGTCATGGGCCT[A/G]GCAGTGGTGCCCTTTGGGGCCGCC
C
Polymorphism: A/G, Transition Substitution
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4) Gene Name: NOS3 rs1007311
Nitric Oxide Synthase 3 (endothelial cell)
Assay ID: C__11631000_1_
Location: Chr. 7 - 150696008
Context Sequence (VIC/FAM):
AGGAGGGCATGAGGCTCAGCCCCAG[A/G]ACCCCCTCTGGCCCACTCCCCAC
AG
Polymorphism: A/G, Transition Substitution

5) Gene Name: NOS3 rs891512
Nitric Oxide Synthase 3 (endothelial cell);ATG9 autophagy related 9 homolog B (S.
cerevisiae)
Assay ID: C___7599646_1_
Location: Chr. 7 - 150708089
Context Sequence (VIC/FAM):
TTCATCCGGGGGTAAGTGAGATGGA[A/G]GACTTGGTGGGGAGCTGCCCAGG
GT
Polymorphism: A/G, Transition Substitution

6) Gene Name: IL6 rs2069845
Interleukin 6 (interferon, beta 2);hypothetical LOC541472
Assay ID: C___1839699_10
Location: Chr. 7 - 22770149
Context Sequence (VIC/FAM):
GTTTCCCAGTCCTCTTTACACCACC[A/G]GATCAGTGGTCTTTCAACAGATCCT
Polymorphism: A/G, Transition Substitution

7) Gene Name: IL6 rs1554606
Interleukin 6 (interferon, beta 2);hypothetical LOC541472
Assay ID: C___9394731_10
Location: Chr. 7 – 22768707
Context Sequence (VIC/FAM):
TTAGTTCATCCTGGGAAAGGTACTC[G/T]CAGGGCCTTTTCCCTCTCTGGCTGC
Polymorphism: G/T, Transversion Substitution
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8) Gene Name: IGF-1 rs2288378
Insulin-like Growth Factor 1 (somatomedin C)
Assay ID: C__16184374_10
Location: Chr. 12 - 102830008
Context Sequence (VIC/FAM):
TTTTATTTGCACAGTCTGTGTCCTT[T/C]TGAATTCCAGCTAGCACCTGAAGAC
Polymorphism: T/C, Transition Substitution
9) Gene Name: IGF-1 rs11111272
Insulin-like Growth Factor 1 (somatomedin C)
Assay ID: C___2801102_10
Location: Chr. 12 - 102827441
Context Sequence (VIC/FAM):
GCAGACACTGTCATCTCATCCTTCT[C/G]TGTTTAGAAGCACTACACTGGGCAT
Polymorphism: C/G, Transversion Substitution

10) Gene Name: APOE rs7412
Apolipoprotein C-I; hypothetical LOC100129500;apolipoprotein E;translocase of outer
mitochondrial membrane 40 homolog (yeast)
Assay ID: C____904973_10
Location: Chr. 19 - 45412079
Context Sequence (VIC/FAM):
CCGCGATGCCGATGACCTGCAGAAG[C/T]GCCTGGCAGTGTACCAGGCCGGG
GC
Polymorphism: C/T, Transition Substitution
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APPENDIX E:
DNA and Plate Preparation Protocol
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DNA Extraction:
1) If frozen, swab was first thawed for approximately ten minutes
2) Place swab in DNA extraction solution (MasterAmp Buccal Swab DNA Extraction Kit)
and rotate in solution a minimum of five times, with the brush being spun against the
walls of the tube to ensure DNA yield.
3) Tubes must then be sealed and swabs disposed of in biohazard bin.
DNA Purification:
1) Vortex solution for 10 seconds.
2) Incubate solution at 60⁰C at 1000 rpm for 30 minutes.
3) Vortex solution for 15 seconds.
4) Incubate solution at 98⁰C at 1000-1400 rpm for eight minutes.
5) Vortex solution for 15 seconds
6) Incubate solution at 98⁰C at 1000-1400 rpm for an additional eight minutes.
7) Vortex solution for 15 seconds
8) Chill tubes on ice briefly to allow tube to cool
9) Centrifuge solution at 4⁰C for five minutes
10) Transfer supernate from original tube to clean tube using 350 µL pipet, being careful not
to include any of the cellular debris at the bottom of the tube in the process
DNA Template Dilution:
1) Thaw DNA for approximately 10 minutes
2) 90 µL added to the first 32 wells of the plate
3) 10 µL of designated, purified DNA added to each well
4) Plate covered with film in order to avoid evaporation of the template
Plate Preparation:
1) Master Mix created, containing 660 µL of Taqman GXTpress Master Mix, 33 µL of
designated probe solution, and 297 µL of water.
2) Mastermix added to the PCR plate in duplicate (62 wells).
3) DNA template added to the Master Mix in duplicate (2 wells for every DNA sample).
4) Film placed over top of plate to avoid spilling and cross contamination.
5) Plate centrifuged, and placed in ABI 7000.
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ANOVA Source Tables
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TableA1: ANOVA Source Table for the Association of the
ACE rs4353 SNP with VO2peak(L·min-1)
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

34133.744a

2

17066.872

.054

.948

45276431.501

1

45276431.501

143.126

.000

34133.744

2

17066.872

.054

.948

Error

8541151.456

27

316338.943

Total

61514682.000

30

8575285.200

29

Corrected Model
Intercept

ACE rs4353

Corrected Total

a. R Squared = .004 (Adjusted R Squared = -.070)

TableA2: ANOVA Source Table for the Association of the
ACE rs4293 SNP with VO2peak(L·min-1)
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

32.461a

1

32.461

.000

.992

41444599.261

1

41444599.261

135.325

.000

32.461

1

32.461

.000

.992

Error

8575252.739

28

306259.026

Total

61514682.000

30

8575285.200

29

Corrected Model
Intercept

ACE rs4293

Corrected Total

a. R Squared = .000 (Adjusted R Squared = -.036)

TableA3: ANOVA Source Table for the Association of the
ACE rs4311 SNP with VO2peak(L·min-1)
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

188115.339

1

188115.339

.628

.435

49592552.006

1

49592552.006

165.561

.000

188115.339

1

188115.339

.628

.435

Error

8387169.861

28

299541.781

Total

61514682.000

30

8575285.200

29

Corrected Model
Intercept

ACE rs4311

Corrected Total

a. R Squared = .022 (Adjusted R Squared = -.013)
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TableA4: ANOVA Source Table for the Association of the
ADRβ2 rs1042717 SNP with VO2peak(L·min-1)
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

17589.343a

1

17589.343

.058

.812

52832565.343

1

52832565.343

172.863

.000

17589.343

1

17589.343

.058

.812

Error

8557695.857

28

305631.995

Total

61514682.000

30

8575285.200

29

Corrected Model
Intercept
ADRβ2 rs1042717

Corrected Total

a. R Squared = .002 (Adjusted R Squared = -.034)

TableA5: ANOVA Source Table for the Association of the
APOE rs7412 with VO2peak(L·min-1)
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

1346.700a

1

1346.700

.004

.948

33625370.700

1

33625370.700

109.811

.000

1346.700

1

1346.700

.004

.948

Error

8573938.500

28

306212.089

Total

61514682.000

30

8575285.200

29

Corrected Model
Intercept

APOE rs7412

Corrected Total

a. R Squared = .000 (Adjusted R Squared = -.036)

TableA6: ANOVA Source Table for the Association of the
IGF-1 rs2288378 with VO2peak(L·min-1)
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

6876.905a

1

6876.905

.022

.882

52623870.372

1

52623870.372

171.965

.000

6876.905

1

6876.905

.022

.882

Error

8568408.295

28

306014.582

Total

61514682.000

30

8575285.200

29

Corrected Model
Intercept
IGF-1 rs2288378

Corrected Total

a. R Squared = .001 (Adjusted R Squared = -.035)
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TableA7: ANOVA Source Table for the Association of the
IGF-1 rs11111272 with VO2peak(L·min-1)
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

851057.740

2

425528.870

1.487

.244

40228530.358

1

40228530.358

140.619

.000

851057.740

2

425528.870

1.487

.244

Error

7724227.460

27

286082.499

Total

61514682.000

30

8575285.200

29

Corrected Model
Intercept
IGF-1 rs11111272

Corrected Total

a. R Squared = .099 (Adjusted R Squared = .033)

TableA8: ANOVA Source Table for the Association of the
IL6 rs2069845 with VO2peak(L·min-1)
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

913211.339

1

913211.339

3.337

.078

53583376.006

1

53583376.006

195.813

.000

913211.339

1

913211.339

3.337

.078

Error

7662073.861

28

273645.495

Total

61514682.000

30

8575285.200

29

Corrected Model
Intercept

IL6 rs2069845

Corrected Total

a. R Squared = .106 (Adjusted R Squared = .075)

TableA9: ANOVA Source Table for the Association of the
IL6 rs1554606 with VO2peak(L·min-1)
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

319029.048a

1

319029.048

1.082

.307

53252262.515

1

53252262.515

180.598

.000

319029.048

1

319029.048

1.082

.307

Error

8256256.152

28

294866.291

Total

61514682.000

30

8575285.200

29

Corrected Model
Intercept

IL6 rs1554606

Corrected Total

a. R Squared = .037 (Adjusted R Squared = .003)
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TableA10: ANOVA Source Table for the Association of
the NOS3 rs1007311 with VO2peak(L·min-1)
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

40111.377a

2

20055.689

.063

.939

47327778.867

1

47327778.867

149.716

.000

40111.377

2

20055.689

.063

.939

Error

8535173.823

27

316117.549

Total

61514682.000

30

8575285.200

29

Corrected Model
Intercept
NOS3 rs1007311

Corrected Total

a. R Squared = .005 (Adjusted R Squared = -.069)

TableA11: ANOVA Source Table for the Association of
the NOS3 rs891512 with VO2peak(L·min-1)
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

12608.441a

1

12608.441

.041

.841

6286770.041

1

6286770.041

20.558

.000

12608.441

1

12608.441

.041

.841

Error

8562676.759

28

305809.884

Total

61514682.000

30

8575285.200

29

Corrected Model
Intercept

NOS3 rs891512

Corrected Total

a. R Squared = .001 (Adjusted R Squared = -.034)

TableA12: ANOVA Source Table for the Association of
the ACE rs4353 with VO2peak(mL·kg-1·min-1)
Dependent Variable:relativeVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

45.152a

2

22.576

.588

.563

12163.602

1

12163.602

316.560

.000

45.152

2

22.576

.588

.563

Error

1037.457

27

38.424

Total

14612.490

30

1082.610

29

Corrected Model
Intercept

ACE rs4353

Corrected Total

a. R Squared = .042 (Adjusted R Squared = -.029)
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TableA13: ANOVA Source Table for the Association of
the ACE rs4293 with VO2peak(mL·kg-1·min-1)
Dependent Variable:relativeVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

1

16.016

.420

.522

10202.600

1

10202.600

267.837

.000

16.016

1

16.016

.420

.522

Error

1066.594

28

38.093

Total

14612.490

30

1082.610

29

Corrected Model
Intercept

ACE rs4293

Corrected Total

16.016

a. R Squared = .015 (Adjusted R Squared = -.020)

TableA14: ANOVA Source Table for the Association of
the ACE rs4311 with VO2peak(mL·kg-1·min-1)
Dependent Variable:relativeVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

1

4.769

.124

.727

13088.433

1

13088.433

340.010

.000

4.769

1

4.769

.124

.727

Error

1077.840

28

38.494

Total

14612.490

30

1082.610

29

Corrected Model
Intercept

4.769

ACE rs4311

Corrected Total

a. R Squared = .004 (Adjusted R Squared = -.031)

TableA15: ANOVA Source Table for the Association of
the ADRβ2 rs1042717 with VO2peak(mL·kg-1·min-1)
Dependent Variable:relativeVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

1

68.931

1.904

.179

13598.531

1

13598.531

375.621

.000

68.931

1

68.931

1.904

.179

Error

1013.679

28

36.203

Total

14612.490

30

1082.610

29

Corrected Model
Intercept
ADRβ2 rs1042717

Corrected Total

68.931

a. R Squared = .064 (Adjusted R Squared = .030)
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TableA16: ANOVA Source Table for the Association of
the APOE rs7412 with VO2peak(mL·kg-1·min-1)
Dependent Variable:relativeVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

63.948a

1

63.948

1.758

.196

7789.185

1

7789.185

214.102

.000

63.948

1

63.948

1.758

.196

Error

1018.662

28

36.381

Total

14612.490

30

1082.610

29

Corrected Model
Intercept

APOE rs7412

Corrected Total

a. R Squared = .059 (Adjusted R Squared = .025)

TableA17: ANOVA Source Table for the Association of
the IGF-1 rs2288378 with VO2peak(mL·kg-1·min-1)
Dependent Variable:relativeVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

29.283a

1

29.283

.778

.385

13553.616

1

13553.616

360.288

.000

29.283

1

29.283

.778

.385

Error

1053.327

28

37.619

Total

14612.490

30

1082.610

29

Corrected Model
Intercept
IGF-1 rs2288378

Corrected Total

a. R Squared = .027 (Adjusted R Squared = -.008)

TableA18: ANOVA Source Table for the Association of
the IGF-1 rs11111272 with VO2peak(mL·kg-1·min-1)
Dependent Variable:relativeVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

31.798a

2

15.899

.409

.669

10601.951

1

10601.951

272.411

.000

31.798

2

15.899

.409

.669

Error

1050.812

27

38.919

Total

14612.490

30

1082.610

29

Corrected Model
Intercept
IGF-1 rs11111272

Corrected Total

a. R Squared = .029 (Adjusted R Squared = -.043)
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TableA19: ANOVA Source Table for the Association of
the IL6 rs2069845 with VO2peak(mL·kg-1·min-1)
Dependent Variable:relativeVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

104.729

1

104.729

2.999

.094

13459.401

1

13459.401

385.388

.000

IL6 rs2069845

104.729

1

104.729

2.999

.094

Error

977.880

28

34.924

Total

14612.490

30

1082.610

29

Corrected Model
Intercept

Corrected Total

a. R Squared = .097 (Adjusted R Squared = .064)

TableA20: ANOVA Source Table for the Association of
the IL6 rs1554606 with VO2peak(mL·kg-1·min-1)
Dependent Variable:relativeVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

1

11.058

.289

.595

13521.255

1

13521.255

353.315

.000

11.058

1

11.058

.289

.595

Error

1071.552

28

38.270

Total

14612.490

30

1082.610

29

Corrected Model
Intercept

IL6 rs1554606

Corrected Total

11.058

a. R Squared = .010 (Adjusted R Squared = -.025)

TableA21: ANOVA Source Table for the Association of
the NOS3 rs1007311 with VO2peak(mL·kg-1·min-1)
Dependent Variable:relativeVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

2

18.701

.483

.622

12570.438

1

12570.438

324.722

.000

37.402

2

18.701

.483

.622

Error

1045.208

27

38.711

Total

14612.490

30

1082.610

29

Corrected Model
Intercept
NOS3 rs1007311

Corrected Total

37.402

a. R Squared = .035 (Adjusted R Squared = -.037)
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TableA22: ANOVA Source Table for the Association of
the NOS3 rs891512 with VO2peak(mL·kg-1·min-1)
Dependent Variable:relativeVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

17.702a

1

17.702

.465

.501

1431.302

1

1431.302

37.634

.000

17.702

1

17.702

.465

.501

Error

1064.908

28

38.032

Total

14612.490

30

1082.610

29

Corrected Model
Intercept

NOS3 rs891512

Corrected Total

a. R Squared = .016 (Adjusted R Squared = -.019)

TableA23: ANOVA Source Table for the Association of
the ACE rs4353 with VO2peak(mL·kgFFM-1·min-1)
Dependent Variable:leanVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

45.940a

2

22.970

.214

.809

37458.014

1

37458.014

348.785

.000

45.940

2

22.970

.214

.809

Error

2899.688

27

107.396

Total

44974.592

30

2945.628

29

Corrected Model
Intercept

ACE rs4353

Corrected Total

a. R Squared = .016 (Adjusted R Squared = -.057)

TableA24: ANOVA Source Table for the Association of
the ACE rs4293 with VO2peak(mL·kgFFM-1·min-1)
Dependent Variable:leanVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

47.137a

1

47.137

.455

.505

31724.382

1

31724.382

306.464

.000

47.137

1

47.137

.455

.505

Error

2898.491

28

103.518

Total

44974.592

30

2945.628

29

Corrected Model
Intercept

ACE rs4293

Corrected Total

a. R Squared = .016 (Adjusted R Squared = -.019)

89

TableA25: ANOVA Source Table for the Association of
the ACE rs4311 with VO2peak(mL·kgFFM-1·min-1)
Dependent Variable:leanVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

.848

1

.848

.008

.929

40421.820

1

40421.820

384.345

.000

.848

1

.848

.008

.929

Error

2944.780

28

105.171

Total

44974.592

30

2945.628

29

Corrected Model
Intercept

ACE rs4311

Corrected Total

a. R Squared = .000 (Adjusted R Squared = -.035)

TableA26: ANOVA Source Table for the Association of
the ADRβ2 rs1042717 with VO2peak(mL·kgFFM-1·min-1)
Dependent Variable:leanVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

288.187

1

288.187

3.036

.092

42306.452

1

42306.452

445.760

.000

288.187

1

288.187

3.036

.092

Error

2657.441

28

94.909

Total

44974.592

30

2945.628

29

Corrected Model
Intercept
ADRβ2 rs1042717

Corrected Total

a. R Squared = .098 (Adjusted R Squared = .066)

TableA27: ANOVA Source Table for the Association of
the APOE rs7412 with VO2peak(mL·kgFFM-1·min-1)
Dependent Variable:leanVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

173.611a

1

173.611

1.754

.196

24367.851

1

24367.851

246.138

.000

173.611

1

173.611

1.754

.196

Error

2772.018

28

99.001

Total

44974.592

30

2945.628

29

Corrected Model
Intercept

APOE rs7412

Corrected Total

a. R Squared = .059 (Adjusted R Squared = .025)
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TableA28: ANOVA Source Table for the Association of
the IGF-1 rs2288378 with VO2peak(mL·kgFFM-1·min-1)
Dependent Variable:leanVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

140.863a

1

140.863

1.406

.246

42166.496

1

42166.496

420.949

.000

140.863

1

140.863

1.406

.246

Error

2804.765

28

100.170

Total

44974.592

30

2945.628

29

Corrected Model
Intercept
IGF-1 rs2288378

Corrected Total

a. R Squared = .048 (Adjusted R Squared = .014)

TableA29: ANOVA Source Table for the Association of
the IGF-1 rs11111272 with VO2peak(mL·kgFFM-1·min-1)
Dependent Variable:leanVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

68.795a

2

34.397

.323

.727

32447.435

1

32447.435

304.530

.000

68.795

2

34.397

.323

.727

Error

2876.834

27

106.549

Total

44974.592

30

2945.628

29

Corrected Model
Intercept
IGF-1 rs11111272

Corrected Total

a. R Squared = .023 (Adjusted R Squared = -.049)

TableA30: ANOVA Source Table for the Association of
the IL6 rs2069845 with VO2peak(mL·kgFFM-1·min-1)
Dependent Variable:leanVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

52.324a

1

52.324

.506

.483

40931.089

1

40931.089

396.111

.000

52.324

1

52.324

.506

.483

Error

2893.305

28

103.332

Total

44974.592

30

2945.628

29

Corrected Model
Intercept

IL6 rs2069845

Corrected Total

a. R Squared = .018 (Adjusted R Squared = -.017)
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TableA31: ANOVA Source Table for the Association of
the IL6 rs1554606 with VO2peak(mL·kgFFM-1·min-1)
Dependent Variable:leanVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

.394

1

.394

.004

.952

41825.045

1

41825.045

397.626

.000

.394

1

.394

.004

.952

Error

2945.234

28

105.187

Total

44974.592

30

2945.628

29

Corrected Model
Intercept

IL6 rs1554606

Corrected Total

a. R Squared = .000 (Adjusted R Squared = -.036)

TableA32: ANOVA Source Table for the Association of
the NOS3 rs1007311 with VO2peak(mL·kgFFM-1·min-1)
Dependent Variable:leanVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

2

48.405

.459

.637

38931.215

1

38931.215

368.975

.000

96.809

2

48.405

.459

.637

Error

2848.819

27

105.512

Total

44974.592

30

2945.628

29

Corrected Model
Intercept
NOS3 rs1007311

Corrected Total

96.809

a. R Squared = .033 (Adjusted R Squared = -.039)

TableA33: ANOVA Source Table for the Association of
the NOS3 rs891512 with VO2peak(mL·kgFFM-1·min-1)
Dependent Variable:leanVO2peak
Source

Type III Sum of
Squares

df

Mean Square

F

Sig.

a

1

31.542

.303

.586

4672.938

1

4672.938

44.900

.000

31.542

1

31.542

.303

.586

Error

2914.086

28

104.074

Total

44974.592

30

2945.628

29

Corrected Model
Intercept

NOS3 rs891512

Corrected Total

31.542

a. R Squared = .011 (Adjusted R Squared = -.025)
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